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Abstract 
The Mediterranean diet is associated with a reduced incidence of chronic inflammatory 
disease and greater life expectancy.  This is in part due to the anti-inflammatory and health 
promoting properties of virgin olive oil (VOO), which is consumed as part of the everyday 
diet amongst the Mediterranean populace.  The oil contains many phenolic compounds, one 
of which is similar to the non-steroidal anti-inflammatory drug (NSAID) ibuprofen in both 
sensory characteristics and anti-inflammatory actions.  Oleocanthal is a VOO phenolic 
compound that produces an irritation specifically in the oropharyngeal region, as does 
ibuprofen.  The sensory perception of the throat irritation evoked from oleocanthal is 
variable, with some individuals reporting greater intensity of irritation in comparison to 
others.  This is suggested to be due to genetic differences in distribution of the sensory 
receptor Transient receptor potential cation channel, subfamily A, member A (TRPA-1).  
Oleocanthal and ibuprofen share an affinity to TRPA-1 receptor located in the oropharynx.  
Genetic variation in taste receptor expression has been reported for the bitter compound 6-
n-propylthiouracil (PROP).  The aim of the first study was to confirm the large variability 
of individual perception of the oropharyngeal specific irritation from oleocanthal and to 
identify hypersensitive (extremely sensitive) and hyposensitive (extremely insensitive) 
individuals to this irritation to participate in study 3.  A second aim was to determine if 
sensitivity to the irritation from oleocanthal is correlated with individual perception of bitter 
taste from PROP, and whether taste or irritant perceptions to these compounds are related 
to aspects of dietary behavior.  The first study contained in this thesis reports that there is 
large inter individual variation in perception of the throat irritation from oleocanthal.  
Furthermore three hypersensitive and three hyposensitive individuals were recruited from 
this screening to take part in study three.  There was no correlation between perceived 
intensity of irritation from oleocanthal and the perceived bitterness of PROP, or a 
relationship between oral perception of these compounds and reported dietary intake, with 
the exception of a correlation between the perceived bitterness of PROP and intake of 
broccoli.  These results add to the literature highlighting the large variation in the way we 
perceive the sensory properties of compounds in foods and also suggest that our sensory 
perception does not always translate to aspects of our diet.  
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Oleocanthal and ibuprofen also target the same inflammatory pathway, Cyclooxygenase 1 
and 2 (COX 1 and 2) and have been shown to exert anti-inflammatory actions in many 
models of chonic inflammatory disease.  NSAIDs have been suggested to have 
unfavourable effects on skeletal muscle growth processes, however the actions of 
olecanthal in muscle had not been explored.  Therefore the aim of the second study in this 
thesis was to observe and compare the effects of the natural NSAID oleocanthal and its 
synthetic counterpart ibuprofen on C2C12 muscle cell proliferation, differentiation, protein 
synthesis and degradation.  Also the anti-inflammatory effects of both NSAIDS were 
observed.  Several novel observations were made in this study.  Oleocanthal and ibuprofen 
had no effect on myoblast proliferation or differentiation.  Both compounds increased 
protein synthesis however had no effect on protein degradation.  Finally pretreatment with 
oleocanthal and ibuprofen similarly attenuated IL-6, iNOS, and TNFα mRNA expression in 
C2C12 myotubes.  These findings highlight oleocanthal as an effective natural NSAID that 
may have beneficial effects on muscle growth and inflammation.  
There is inter-individual variation in the perception of the oropharyngeal irritation produced 
by oleocanthal.  It may be that the way an individual perceives the sensory properties of a 
compound in food is linked to the pharmacological actions of that compound in the body.  
The primary aim of the third study was to determine if oleocanthal and ibuprofen 
differentially influence protein synthesis, degradation and inflammation in primary human 
muscle cells derived from those classified as hypersensitive (extremely sensitive) and 
hyposensitive (extremely insensitive) to the throat irritation of oleocanthal.  Differences in 
TRPA-1 mRNA expression in muscle were also assessed.  The findings from the final 
study report that cells derived those who are hyposensitive to the throat irritation had 
greater TRPA-1 expression after LPS challenge than those hypersensitive.  Cells derived 
from those hypersensitive had greater expression of IL-8 after LPS challenge.  Oleocanthal 
and ibuprofen also increased protein synthesis in those hyposensitive compared to 
hypersensitive while having no effect on protein degradation.  While these results indicate 
there may be a link between sensory perception and molecular processes, a differential 
treatment effect from oleocanthal and ibuprofen could not be shown.  However in human 
myotubes pretreatment with oleocanthal and ibuprofen attenuated expression of IL-6, IL-8, 
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and TNFα, but had no effect on MCP-1 mRNA expression.  These findings suggest that 
there may be a link between the perceived intensity of the irritant properties of oleocanthal, 
therefore possibly sensory TRPA-1 levels, and the systemic responses to endotoxin induced 
inflammation and also protein synthesis in vitro.  These results also suggest that oleocanthal 
is an effective NSAID in human muscle cells and acts similarly to its synthetic counterpart 
ibuprofen. 
The findings from this thesis expand on the knowledge of a potential link between the 
sensory characteristics of compounds in foods and the pharmacological actions that the 
compound has in the body.  Oleocanthal has been shown to increase protein synthesis in 
muscle and attenuate inflammatory cytokines that may interrupt skeletal muscle metabolic 
processes.  Therefore oleocanthal may be a future therapeutic compound important in the 
quest to find anti-inflammatory compounds that reduce inflammation and improve skeletal 
muscle health. 
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1 Literature Review 
1.1  Introduction 
The health promoting attributes associated with following a traditional Mediterranean diet 
have been recognised for decades, with the first suggestion of healthful effects 
accompanying the Seven Countries Study (Keys 1970).  The risk of chronic inflammatory 
disease in Mediterranean populations are the lowest in the world, and life expectancy 
amongst the highest (WHO 2009), which has earned the populations residing along the 
Mediterranean sea considerable attention from nutrition researchers worldwide.  Since the 
inaugural Seven Countries Study numerous other studies have supported the view that this 
pattern of eating has been associated with a reduced incidence of inflammatory disease 
states (de Lorgeril, Salen et al. 1998, Singh, Dubnov et al. 2002, Stark and Madar 2002, 
Mitrou, Kipnis et al. 2007, Sexton, Black et al. 2012, Boccardi, Esposito et al. 2013, Di 
Daniele, Petramala et al. 2013, Estruch, Ros et al. 2013, van de Laar, Stehouwer et al. 2013, 
Kenfield, DuPre et al. 2014, Lopez-Garcia, Rodriguez-Artalejo et al. 2014, Peñalvo, Oliva 
et al. 2015).  
 
The principle source of dietary fat in the Mediterranean diet is virgin olive oil (VOO) 
(Bach-Faig, Berry et al. 2011)  and this has in part been recognised as a contributing factor 
towards the favourable health profile that the Mediterranean population possess (Urpi-
Sarda, Casas et al. 2012).  Throughout history VOO has been recognized as valuable 
pharmacological agent in the hands of ancient Greek doctors (Caramia, Gori et al. 2012).  
Hippocrates mentions approximately 60 health conditions where VOO use can be 
beneficial, for example many skin conditions, wounds and burns, amongst others.  
Typically traditional Mediterranean populations consume 25-50 ml of oil daily as part of 
their diet, generally in salad dressings as well as cooked foods (Corona, Spencer et al. 
2009).     
 
Importantly VOO contains approximately 36 phenolic compounds, and it is this minor 
phenolic fraction of VOO that is partially responsible for the health benefits that 
accompany intake (Bayram, Ozcelik et al. 2012, Cicerale, Lucas et al. 2012, Parkinson and 
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Keast 2014, Virruso, Accardi et al. 2014).  An expanding volume of studies (including 
human, in vivo and in vitro) have reported that VOO phenolics have beneficial effects on 
inflammation, antioxidant status, antimicrobial activity, as well as other biological markers 
of non- communicable disease. (for review see (Cicerale, Lucas et al. 2011)). 
 
A phenolic compound in VOO that stands alone compared to other VOO compounds in 
terms of sensory and anti-inflammatory attributes is decarboxy methyl ligstroside aglycone 
(AKA oleocanthal) (Beauchamp, Keast et al. 2005).  Oleocanthal is homologous with the 
non-steroidal anti-inflammatory drug (NSAID) ibuprofen (Beauchamp, Keast et al. 2005) 
for both perceptual and anti-inflammatory properties.  Both compounds produce a localised 
irritation in the oropharangeal region and further research instigated, because of the 
perceptual similarities, found that oleocanthal shares a similar anti-inflammatory action 
with ibuprofen (Beauchamp, Keast et al. 2005),  therefore oleocanthal is now 
acknowledged as a naturally occurring NSAID (Li, Sperry et al. 2009, Pitt, Roth et al. 
2009, Elnagar, Sylvester et al. 2011, Monti, Margarucci et al. 2011, Scotece, Gómez et al. 
2012, Akl, Ayoub et al. 2014). 
 
Importantly it has been proposed that the long term daily ingestion of oleocanthal, 
contained in VOO, is likely to contribute to the favorable health profile of Mediterranean 
populations (Beauchamp, Keast et al. 2005).  Chronic low doses of ibuprofen and other 
cyclooxygenase (COX) inhibitors such as aspirin have been shown to have anti-
carcinogenic and anti-thrombotic effects (Garcia-Rodriguez and Huerta-Alvarez 2001, 
Hennekens 2002, Harris, Beebe-Donk et al. 2006, Ma, Liu et al. 2011, Mubeen, KR et al. 
2011).  Therefore, it is plausible that low, chronic doses of a naturally occurring NSAID 
such as oleocanthal may attenuate inflammation over time, and may then contribute to 
significant prevention of the development of chronic inflammatory disease. 
 
1.2 Oleocanthal identification 
Oleocanthal was first documented in literature as a phenolic compound contained in VOO 
in the early 90’s (Montedoro and Servili 1993).  It was a decade later that the compound, 
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then known as decarboxy methyl ligstroside aglycone, was suggested to be the sole 
phenolic responsible for the distinct throat irritation and pungency elicited by some VOOs 
(Davies and Avery 1971).  Beauchamp and colleagues, substantiated this finding over a 
decade later reporting that decarboxy methyl ligstroside aglycone was the sole irritant 
phenolic responsible for the peppery stinging sensation experienced with VOO ingestion 
and aptly named the compound oleocanthal (oleo for olive, canth for sting, and al for 
aldehyde) (Beauchamp, Keast et al. 2005).     
 
The confirmatory finding that oleocanthal is the sole irritating compound in VOO was 
achieved by quantifying oleocanthal from various VOO’s and measuring the throat 
irritation accompanying ingestion (Beauchamp, Keast et al. 2005).  However to exclude the 
possibility that other compounds in VOO may also contribute to the unique perceptual 
characteristic, oleocanthal was synthesised and dissolved in corn oil.  The measure of the 
throat irritation from the addition of oleocanthal to non- irritating corn oil was found to be 
dose dependent on oleocanthal and mimicked the irritation of VOO (Beauchamp, Keast et 
al. 2005) confirming that indeed oleocanthal is the sole compound responsible for throat 
irritating sensation.   
 
A point of interest is that the spatial irritation produced by oleocanthal is specific to the 
oropharyngeal region.  Generally irritant or pungent compounds are perceived in all regions 
in the oral cavity, rather than isolated to a spatially distinct area which led to speculation 
that a sensory receptor specific to oleocanthal exists in the oropharyngeal region (Cicerale, 
Breslin et al. 2009).  Peyrot des Gachons and colleagues have identified the Transient 
receptor potential cation channel, subfamily A, member 1 (TRPA1) as the receptor linked 
to oleocanthal (Peyrot des Gachons, Uchida et al. 2011).  TRPA-1 is also linked to 
neurogenic pain and inflammatory processes (Bautista, Pellegrino et al. 2013, Schwartz, La 
et al. 2013, Trevisan, Hoffmeister et al. 2014).  We now know that there is large inter-
individual variation in sensitivity to oleocanthal and this may then be due to variation in 
expression of TRPA1 receptors in the oropharyngeal region (Cicerale, Breslin et al. 2009, 
Bennett and Hayes 2012). 
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1.3 Sensory and anti-inflammatory profile of oleocanthal 
A key indicator of VOO quality is pungency and irritation.  These attributes are recognised 
as the positive reinforcement of VOO quality by those who frequently consume the oil, 
such as Mediterranean populations (Peyrot des Gachons, Uchida et al. 2011).  So much so, 
that prized VOO’s are rated as one cough or two cough oils, with the latter classed as 
superior (Peyrot des Gachons, Uchida et al. 2011).  Although the concentration of 
oleocanthal differs amongst oils and may influence irritant properties of the oil, there is 
another key factor.  As mentioned there are differences in the way individuals perceive the 
irritancy of oleocanthal in VOO.  The degree in which an individual experiences bitterness 
or irritation of a compound is determined by an individual’s sensitivity to the compound, 
and large inter-individual variation in the perceived intensity of irritation of oleocanthal has 
been reported (Cicerale, Breslin et al. 2009, Bennett and Hayes 2012).  Cicerale and 
colleagues (Cicerale, Breslin et al. 2009) reported that intensity ratings of irritation to a 
oleocanthal concentration of 54 mg/kg, contained in the VOO matrix, ranged from a slight 
irritation in the throat, to an irritation that was of intensity sufficient to produce a cough in 
those highly sensitive.   
 
Fischer and colleagues hypothesised that similar perceptual properties may be reflective of 
similar pharmacological properties as early as 1965, suggesting that the more pronounced 
the perceptual properties, the more potent the pharmacological properties (Fischer, Griffin 
et al. 1965).  For example, the more bitter tasting a compound is rated, the more potent the 
anti- inflammatory, anti-oxidant, or anti- microbial actions of that compound may be.  This 
may have important implications for investigations into suitable naturally occurring 
NSAIDs.  We may speculate that if levels of TRPA-1 are expressed in a coordinated 
manner throughout the body, and greater expression results in higher oropharyngeal 
irritation, then perhaps muscle and other tissue would also have high expression levels of 
TRPA-1 receptor.  To elaborate, oleocanthal sensitivity is linked to variation in 
oropharyngeal TRPA-1 levels, and TRPA-1 is activated in response to inflammatory 
cytokines (Bautista, Pellegrino et al. 2013).  Therefore differences in oral sensitivity may 
indicate how oleocanthal influences inflammatory pathways in muscle (figure 1.1).  An 
objective of this thesis is to determine if oleocanthal differentially attenuates inflammation 
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based on individual differences in perceptual sensitivity to the oropharyngeal irritation 
elicited by this phenolic compound.  
As mentioned a link in sensory attributes between oleocanthal and ibuprofen was 
established and after this discovery Beauchamp and colleagues (Beauchamp, Keast et al. 
2005) explored the possibility that the pathway of anti-inflammatory activity was also 
analogous between compounds.  The results of the study clearly show that oleocanthal 
inhibits cyclooxygenase 1 and 2 (COX 1 &2) enzymes in a dose-dependent manner, and 
does in fact mimic the anti-inflammatory action of the synthetic NSAID ibuprofen.  The 
important and novel findings of Beauchamp and colleagues (Beauchamp, Keast et al. 2005) 
demonstrate that oleocanthal not only mimics the mode of ibuprofen inflammatory 
 
 
Figure 1.1: It is possible that receptor levels of TRPA-1 in muscle reflect levels in the 
oropharyngeal region. Therefore low or high levels of TRPA-1 in the oropharyngeal region 
may reflect the inflammatory responses in muscle through activation of P38 MAPK 
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activity, but inhibits COX 1 and COX 2 enzymes significantly more at equimolar 
concentrations.  For example, oleocanthal (25 μM) inhibits 41-57% of COX activity in 
comparison to ibuprofen (25 μM) which inhibits 13-18% of COX activity.  This adds 
further weight to oleocanthal as a potential factor in the health benefits associated with a 
traditional Mediterranean Diet.  Assuming approximately 70% absorption, then 50 ml /day 
corresponds to approximately 10% the current ibuprofen pain relieving dose.  
Mediterranean populations generally consume ~30 ml daily so the therapeutic effects of 
oleocanthal may be beneficial as a low dose over time.  
The sensory characteristics of oleocanthal have now been discussed and it is also important 
to review the potential pharmacologic properties of this phenolic that have been highlighted 
in the literature over the last decade.  
1.4 Oleocanthal and inflammatory disease 
Since the discovery of oleocanthal and the subsequent findings that this compound is a 
natural NSAID homogeneous with ibuprofen, several studies have been conducted to 
confirm the pharmacological actions of oleocanthal in different models of disease.  The 
following discusses these studies. 
1.4.1 Oleocanthal and cancer 
There is an abundance of associative evidence highlighting the lower incidence of many 
types of cancer, including breast, prostate, lung and gastrointestinal cancer that are 
observed in Mediterranean populations when compared to Western populations (de 
Lorgeril, Salen et al. 1998, Dixon, Subar et al. 2007, Reedy, Mitrou et al. 2008, Anna, 
Mimi et al. 2009, Gonzalez and Riboli 2010).  Numerous in vitro studies have reported that 
oleocanthal  inhibits the initiation and metastasis of several types of cancer in disease 
models including skin cancer (Khanal, Oh et al. 2011), bone cancer (Scotece, Gómez et al. 
2012), colon and breast cancer (Elnagar, Sylvester et al. 2011).  Recent research has 
unveiled a therapeutic effect from oleocanthal on heat shock protein 90 (Hsp90) 
(Margarucci, Monti et al. 2013).  Hsp90 is a chaperone protein that stabilizes a number of 
proteins that are required for tumor growth.  Therefore Hsp90 inhibitors are investigated as 
anti-cancer drugs.  Margarucci and colleagues (2013) report that oleocanthal significantly 
reduce two Hsp90 proteins, Akt and Cdk4 without actually influencing Hsp90 regulation.   
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Furthermore oleocanthal had a pro-apoptotic effect on cancer cells but only a slight effect 
on the viability of peripheral blood mononuclear cells, which is a common attribute of 
Hsp90 inhibitors.  It would therefore seem that oleocanthal may be a compound of interest 
in regards to endeavours to identify a new class of Hsp90 inhibitors (Margarucci, Monti et 
al. 2013), and is a compound of importance in future cancer research.      
1.4.2 Oleocanthal and joint-degenerative disease 
Oleocanthal has recently been highlighted as a therapeutic compound that may be of 
interest in the quest to find suitable natural NSAIDs for the treatment of joint degenerative 
disease.  Osteoarthritis (OA) is characterized by the spontaneous release of Nitric Oxide 
(NO)  from diseased chrondocytes  (Lei, Wang et al. 2012).  NO  plays a pivotal role in 
joint-degenerative disease and the stable end product of NO, nitrite (NO2), is significantly 
expressed in arthritic synovial fluid (Tung, Venta et al. 2002).  NO is biosynthesized by 
nitric oxide synthase (NOS).  Another form of NOS is inducible NOS (iNOS) which is 
primarily responsible for the inflammatory actions of NOS (Espey, Miranda et al. 2000) .  
Iacano and colleagues (2010) reported that oleocanthal and synthesized derivatives, 
attenuate production of iNOS protein expression in an LPS challenged murine 
chondrocytes, in a dose dependent manner (Iacono, Gómez et al. 2010).   
 
Scotece and colleagues (2012) investigated the effects of oleocanthal exert on potential 
targets of joint inflammation reporting that oleocanthal inhibits NO production in J774 
macrophages and inhibits both interleukin 6 (IL-6) and Macrophage inflammatory protein 1 
alpha (MIP-1α) in both ATDC5 chrondocytes and J774 macrophages (Scotece, Gómez et 
al. 2012).  These inflammatory cytokines are both implicated in the inflammatory process 
and cartilage destruction of inflammatory arthropathies (Kokkonen, Söderström et al. 2010, 
Murakami and Nishimoto 2011).  Further to this, oleocanthal decreased expression of other 
pro-inflammatory markers Interleukin 1 (IL-1), tumour neurosis Factor (TNFα), and 
granulocyte-macrophage colony-stimulating factor (GM-CFS) (Scotece, Gómez et al. 
2012).  This study not only investigated the anti-inflammatory effects of oleocanthal in 
chondrocytes but also macrophages which is relevant as synovial macrophages generate the 
inflammatory cascade occurring in synovial fluid that leads to OA and rheumatoid arthritis 
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(RA) (Scotece, Gómez et al. 2012) .  Subsequently these authors suggest that there is a 
justification for oleocanthal to be developed as a therapeutic agent for future treatment of 
joint degenerative disease.               
1.4.3 Oleocanthal and brain health 
Ibuprofen is known to exert beneficial effects on markers of neuro-degenerative disease 
(Van Dam, Coen et al. 2008, Dong, Yan et al. 2014, Zaminelli, Gradowski et al. 2014), 
therefore it was seen as logical to investigate oleocanthal’s role as a natural  
pharmacological agent, based on similarities between compounds in both perceptual and 
anti-inflammatory properties.  Li and collegues (Li, Sperry et al. 2009) have presented 
important findings demonstrating that oleocanthal inhibits tau fibrillization in vitro by 
forming an adduct with PHD Finger protein 6 (PHF6) peptide.  PHF6, is a VQIXXK motif 
that resides in the microtubule binding region (Li and Virginia 2006).  Common lesions that 
are observed in neuro-degenerative disease (i.e. Alzheimer’s disease) are 
hyperphosphorylated tangles of tau and the PHF6 peptide enables the phosphorylation of 
tau.  Therefore as oleocanthal modifies the PHF6 peptide it then disturbs tau-tau interaction 
and the subsequent fibril formation.   
 
Motivated to discover the mechanism by which oleocanthal reacts with the tau protein  
Monti and colleagues (Monti, Margarucci et al. 2011)  reported that oleocanthal covalently 
modifies the construct of tau referred to as K18 in biologically relevant conditions (Monti, 
Margarucci et al. 2011).  Oleocanthal cross linked with two lysine residues and the end 
result was the rearrangement of the skeleton producing a more stable piridinium like 
complex (Monti, Margarucci et al. 2011).     
 
Another type of lesion that are characteristic of Alzheimer’s disease are Β-amyloid peptides 
(Aβ) (Guela, Wu et al. 1998).  Derived from Aβ are diffusible ligands (ADDLs) which are 
neurotoxic factors believed to initiate the onset of Alzheimer’s disease (Pitt, Roth et al. 
2009). In vitro evidence suggests that  oleocanthal alters the structure of ADDLs and 
augments antibody clearance of ADDLs, therefore protecting hippocampal neurons from 
ADDL toxicity (Pitt, Roth et al. 2009).  A cross sectional Australian study concluded that 
those suffering neurodegenerative disease showed a significantly lower adherence to a 
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Mediterranean style dietary pattern (Des Gachons, Beauchamp et al. 2009), and there is a 
plethora of evidence showing up to a 40% decrease in Alzheimer’s disease in populations 
consuming a Mediterranean style diet (Scarmeas, Luchsinger et al. 2009).  Perhaps 
oleocanthal, in conjunction with other phenolics, exert a neuro-therapeutic potential that is 
reflected in the low incidence of neurodegenerative disease in populations that regularly 
consume the oil.  To date there have been no studies to identify oleocanthal as a possible 
therapeutic agent in skeletal muscle.  An overview of in vitro studies and the potential 
beneficial effects that oleocanthal exerts on several disease models is included in table 1.1.  
 
As reviewed Oleocanthal has been highlighted to have potent anti-inflammatory and 
pharamacological properties in several models of disease.  This compound is similar in 
terms of sensory and anti-inflammatory actions to ibuprofen, and ibuprofen has been 
suggested to have an effect on skeletal muscle and growth.  Oleocanthal’s anti-
inflammatory actions have not been investigated in muscle previously so the next section of 
this review will focus on skeletal muscle health, inflammation, and general NSAID use.    
1.5 Muscle regeneration and growth 
It is estimated around 30-40% of the mass of the human body is comprised of muscle and 
impairment may not only lead to loss of function and instability, but also disease and injury 
(Russell 2010).  Not only is skeletal muscle atrophy a result of chronic inflammatory 
disease it is associated with below average prognosis in several diseases, including 
muscular dystrophies (Ohsawa, Okada et al. 2012), and chronic inflammatory disease states 
such as cancer (Wang, Lai et al. 2011), diabetes (Sexton, Black et al. 2012), sepsis and 
heart failure (Fülster, Tacke et al. 2012) and is a strong predictor of morbidity and mortality 
associated with chronic inflammatory disease (Cruz-Jentoft, Landi et al. 2010, Fearon, 
Evans et al. 2011, Foletta, White et al. 2011).   
 
Therefore it is of great interest and importance to focus on compounds that can positively 
impact muscle regeneration and growth. 
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Table 1.1: Beneficial health effects of Oleocanthal 
Reference  Reported effects of oleocanthal Potential inflammatory disease target 
(Beauchamp, 
Keast et al. 
2005) 
Dose dependent Inhibition of COX-1 and COX-2  
identical to ibuprofen 
COX induced disease states such as 
CVD, cancer  
(Pitt, Roth et al. 
2009) 
Altered oligomerization state of ADDLs. Blocking of 
synaptic deterioration , enhanced anti-body clearance, 
potential anti-inflammatory and antioxidant benefits in 
Alzheimer prevention 
Alzheimer’s disease 
(Li, Sperry et 
al. 2009) 
 
 
 
 
 
(Monti, 
Margarucci et 
al. 2011) 
Inhibitory effect on tau fibrilisation  by forming an 
adduct with lysine residue in PHF6 peptide and results 
in the disruption of tau-tau interaction and subsequent 
inhibition of tau filament assembly 
 
Covalently modifies the construct of tau referred to as 
K18 in biologically relevant conditions disturbs tau-tau 
interaction and the subsequent fibril formation. 
Neurodegenerative disorders such as 
Alzheimer’s, Parkinson’s disease, 
and dementia 
(Scotece, 
Gómez et al. 
2012) 
 
(Collins and 
Partridge 2005) 
Suppression of LPS induced  iNOS in ADTC human 
chrondocytes  
 
NO production in J774 macrophages and inhibits both 
IL-6 and MIP-1α in both ATDC5 chrondocytes and 
J774 macrophages 
Inflammatory degenerative joint 
diseases such as osteoarthritis 
(Schaffer, 
Florin et al. 
2006) 
 
(Khanal, Oh et 
al. 2011) 
 
 
 
 
 
 
(Elnagar, 
Sylvester et al. 
2011) 
 
Significantly reduces 2 Hsp 90 proteins 
 
 
Inhibition of extracellular signal-regulated kinases 1/2 
and p90RSK phosphorylation.JB6 in Cl41cells. 
encourages cell apoptosis by activating caspase-3 and 
poly-adenosine diphosphate-ribose polymerase, 
phosphorylates p53 (Ser15), and also induces the 
fragmentation of DNA in HT-29 cells derived from 
human colon adenocarcinoma 
 
Encourages cell apoptosis by activating caspase-3 and 
poly-adenosine diphosphate-ribose polymerase, 
phosphorylates p53 (Ser15), and also induces the 
fragmentation of DNA in HT-29 cells derived from 
human colon adenocarcinoma 
 
Potential anti-cancer drug as a Hsp 
90 inhibitor 
 
Anti-proliferative effect in cancer 
cells 
 
 
 
 
 
 
Encourages cancer cell apoptosis 
 
 
Human skeletal muscle regenerates in response to insult and injury and this regenerative 
ability is a balance of various cellular and molecular responses (Schiaffino, Sandri et al. 
2007).  The coordination between inflammation and regeneration is important for a positive 
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outcome following muscle damage.  Regeneration and repair to skeletal muscle is a process 
that employs two factors, degeneration and regeneration (Turner and Badylak 2012).  
Embryonic muscle development begins with myoblast proliferation which generate muscle 
precursors, then differentiation and fusing occurs resulting in the formation of 
multinucleated muscle fibers.  During adult muscle regeneration satellite cells, which are 
skeletal muscle stem cells, proliferate, differentiate and fuse to repair injured muscle and 
restore function (Figure 1.2).  The regenerative ability of muscle diminishes with disease 
and aging and this can be linked directly to a decrease in satellite cell activity (Renault, 
Thorne et al. 2002, Chakkalakal, Jones et al. 2012).  
 
Muscle health is also an intricate balance between protein synthesis and protein degradation.  
When the rate of protein synthesis exceeds that of degradation hypertrophy results.  
Conversely when protein degradation exceeds protein synthesis skeletal muscle atrophy 
occurs (Bodine, Latres et al. 2001, Léger, Cartoni et al. 2006).  Both catabolic and anabolic 
pathways regulate these processes and several signaling pathways involved in mediation of 
skeletal muscle hypertrophy and protein synthesis have been reported, including the IGF-
1/PI3K/AKT pathway.  Acute transforming retrovirus thymoma (AKT) protein has been 
highlighted as an integral factor in both hypertrophy and atrophy signaling pathways and 
exerts dual action in the formation of new protein, whilst preventing the potential 
degradation of existing protein (Cho, Mu et al. 2001, Rommel, Bodine et al. 2001).  As a 
result, Akt is a key metabolic control point in a number of diseases that are characterized by 
changes in muscle mass (Favier, Benoit et al. 2008, Russell 2010).  Once activated AKT has 
been shown to increase protein synthesis via the mammalian target of rapamycin (mTOR) 
and glycogen synthase kinase- 3β (GSK-3β) (Léger, Cartoni et al. 2006, Russell 2010).  The 
mechanism of how AKT and other signaling proteins regulate skeletal muscle protein 
synthesis is still emerging and further research is required for the identification of 
therapeutic targets in the control of muscle wasting accompanying skeletal muscle catabolic 
disease. 
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Figure 1.2: Skeletal Muscle regeneration in response to muscle damage. Adult muscle fibres 
contain quiescent satellite cells that upon stimulation become myoblasts, proliferate, 
differentiate and fuse with existing fibres. Each step of the muscle regeneration process is 
controlled by many transcriptional factors.  
 
Both oleocanthal and ibuprofen are anti-inflammatory compounds and so therefore it is of 
importance to review the effects of inflammation with a focus on skeletal muscle health.  
 
1.6 Inflammation 
Oleocanthal, a natural NSAID and ibuprofen a synthetic NSAID are both recognized as 
being effective anti-inflammatories in several models of disease (Purssell 2011, Wilkinson, 
Cramer et al. 2012, Parkinson and Keast 2014).  Throughout evolution of species, 
contracting infectious diseases would inevitably end in death, so the ability to fight off 
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pathogens and recover from injury was crucial (Van Bodegom, May et al. 2007).  The 
complex processes of inflammation are finely tuned to restore the organism to a state of 
homeostasis after injury or infection. The short term inflammatory response, defined as 
acute inflammation, eliminates infections and promotes tissue repair.  Any disruption to 
tissue homeostasis activates the innate immune cells (mast cells, leukocytes, and dendrite 
cells).  
 
Chemokines, which are chemotactic molecules induced by secreted cytokines such as TNF, 
initially attract these immune cells to the site of injury and infection.  If the resolution of 
inflammation is delayed, or deregulated, chronic inflammation can ensue and macrophages 
are then recruited along with T-cells (Germano, Allavena et al. 2008). When in a state of 
homeostasis, macrophages assist in maintaining the basal state of the tissue and assist in 
regulatory functions such as maintaining adipocyte metabolism and osteocyte activity 
(Gordon and Taylor 2005).  If the homeostatic environment of the body is disrupted then 
macrophage activity may become deregulated and tissue malfunction may occur (Medzhitov 
2008).  This may result in macrophages secreting increased amounts, or different types of 
growth factors and signals.  Alternatively, more macrophages may be recruited to the tissue 
as a result and consequently produce a toxic microenvironment (Medzhitov 2008).  This 
disruption to tissue homeostasis, and in effect tissue malfunction, produces a low grade 
chronic inflammatory state over time.  Therefore, if the initial acute response does not 
resolve the pathogen intrusion then the inflammatory response will continue and the 
subsequent inflammatory microenvironment may lead to the initiation of disease (Karin 
2006, Packard and Libby 2008, Kamp, Shacter et al. 2011).  Of importance is that chronic 
inflammation can significantly contribute to the decreased regenerative properties of skeletal 
muscle that is associated with disease and aging (Martinez-Gonzalez, Bes-Rastrollo et al. 
2009). 
 
1.6.1 Inflammatory markers and skeletal muscle health 
As mentioned muscle health is an intricate balance of cell growth and cell death and chronic 
inflammatory disease can disrupt important metabolic processes.  Uncontrolled chronic 
inflammation is not only implicated in disease states such as cancer, Alzheimer’s, and 
Chapter One – Literature Review 
________________________________________________________________________________________________ 
 
15 
 
arthritis but also muscle wasting disease such as sarcopenia and muscle cachexia.  The 
inflammatory mediators can have detrimental effects on tissue regenerative properties either 
directly or via the activation inflammatory pathways or the production of reactive 
byproducts, both of which may suppress satellite cell activation or damage muscle satellite 
cells (Huard, Li et al. 2002, Jang, Sinha et al. 2011).  Tumour necrosis factor alpha (TNF α) 
plays a significant role in the inflammatory cascade producing not only immunity but at high 
levels cell death and inflammation (Walczak 2011).  Signaling through TNF-α pathways has 
powerful effects on skeletal muscle.  In vitro, excess activity of TNF-α directly blocks 
anabolic actions of several growth factors and adversely affects protein synthesis (Strle, 
Broussard et al. 2004) as well as inhibiting muscle differentiation in vitro and in vivo animal 
models (Argiles, Alvarez et al. 2000, Coletti, Yang et al. 2002, Coletti, Moresi et al. 2005) .  
 
Interleukin 6 (IL-6) is an intercellular signaling molecule and is a  pro-inflammatory 
cytokine that is associated with several disease states and also produces catabolic effects in 
skeletal muscle (Haddad, Zaldivar et al. 2005).  Il-6 is often reported to be over expressed in 
metabolic syndrome and there are suggestions that IL-6 may negatively affect skeletal 
muscle growth and contribute to the catabolic effects observed in chronic inflammatory 
disease states (Goodman 1994, Bodell, Kodesh et al. 2009, Goodman, Levine et al. 2009).  
IL-6 is elevated with aging and sepsis and cancer and is induced by the endotoxin 
lipopolysaccharide (LPS) (Frost, Nystrom et al. 2003).  Several laboratories have 
demonstrated that IL-6 is elevated in human and mouse myoblasts after stimulus with LPS 
(Frost, Nystrom et al. 2003)  and it has been highlighted numerous times that both IL-6 and 
TNF α have an integral role in muscle wasting disease such as sarcopenia (Hall, Ma et al. 
2011). 
 
Inducible NOS (iNOS; or NOS2), is a form of nitric oxide (NO) which is a much studied 
inflammatory mediator.  iNOS is primarily involved in the inflammatory actions of NOS 
and is generally not present in resting cells but is induced by various stimuli, which include 
challenge by bacterial lipopolysaccharide (LPS) (Iacono, Gómez et al. 2010).  iNOS has 
recently been shown to be an integral mediator of TNF α induced muscle wasting and is now 
a potential target in the quest to discover therapeutic strategies that may prevent or alleviate 
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muscle loss and chronic inflammatory disease (Hall, Ma et al. 2011).  As previously 
discussed oleocanthal has been highlighted to attenuate iNOS expression in chrondocytes. 
In summation it has been observed that a high level of inflammation is correlated with low 
muscle mass and decreased muscle function which is of serious concern (Schaap, Pluijm et 
al. 2006, Schaap, Pluijm et al. 2009).  Therefore it is important to identify anti-inflammatory 
compounds to reduce systemic inflammation and protect against both chronic inflammatory 
disease and the debilitating effects of muscle loss. Oleocanthal is homogulous with the 
synthetic NSAID ibuprofen therefore the following section will discuss ibuprofen and its 
anti-inflammatory actions, focusing on a potential influence that this drug may exert on 
skeletal muscle health. 
 
1.6.2 Ibuprofen and NSAIDs 
Of interest due to the established pharmacological similarities with oleocanthal is the 
NSAID ibuprofen.  Endeavours to find a superior and safe NSAID for the treatment of 
arthritis lead to the development of ibuprofen in the early 1960’s.  Ibuprofen was the first 
NSAID licensed for sale over the counter in the United Kingdom in 1983 based on its 
efficiency and safety profile in comparison to other NSAIDs that were available without 
prescription (Rainsford 2013).  Ibuprofen is generally thought to be the least toxic among 
the NSAIDs and has the fewest adverse side effects, which may be reflective of the low 
doses recommended and its short half -life (1-2hours)(Henry, Lim et al. 1996).  
 
Ibuprofen inhibits COX1 and COX2 enzymes in a dose dependent manner and subsequently 
blocks inflammatory prostaglandin synthesis (Lanza, Chan et al. 2009).  Although ibuprofen 
is considered comparably safe compared with other NSAIDs, it does have serious side-
effects.  Long term use of ibuprofen at high anti-inflammatory doses (>2400 mg) inflicts 
damage on the gastric mucosa (Sostres, Gargallo et al. 2013, Bello, Kent et al. 2014) and 
impairs renal function (Bagnoli, Rossetti et al. 2013).  However at low analgesic doses 
(1200mg) ibuprofen seems to inflict no greater gastrointestinal damage than a placebo  and 
is well tolerated (Rainsford 2009).  Therefore, low doses of ibuprofen over a short time 
frame are believed to be safe in respect to gastrointestinal toxicity, however chronic 
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inflammatory conditions such as arthritis require higher doses (~2400mg) and long term use 
(Schiff and Peura 2012, Salvo, Antoniazzi et al. 2014) .  Ibuprofen has been shown to have 
beneficial effects in the treatment of Alzheimer’s disease (Pinnen, Sozio et al. 2011, 
Brownell, Jokivarsi et al. 2012, Wilkinson, Cramer et al. 2012, Matsuura, Otani et al. 2015) 
and has been reviewed to be effective in treating both osteoarthritis and rheumatoid arthritis 
(Adatia, Rainsford et al. 2012, Danvers and Varadi 2013).  In addition to the attenuation of 
COX enzymes ibuprofen can inhibit the inflammatory agents TNFα, and IL-6 (Sironi, 
Gadina et al. 1992, Gallelli, Galasso et al. 2013, Trappe, Standley et al. 2013).  However 
ibuprofen has been shown to increase expression of IL-6, IL-10, IL-8, IL-1ra, granulocyte 
colony-stimulating factor (GCS-F), monocyte chemotactic protein 1 (MCP-1), and 
macrophage inflammatory protein 1 beta (MIP -1β), but not TNFα after endurance exercise 
(Nieman, Henson et al. 2006).    
 
Satellite cells are myogenic stem cells that reside between the basal lamina and sarcolemma 
of muscle fibres and have a crucial role in muscle regeneration processes.  NSAID use may 
impede satellite cell activity as suggested in both human and animal models in vitro and in 
vivo (Shen, Li et al. 2005, Soltow, Betters et al. 2006, Mackey, Kjaer et al. 2007, 
Mikkelsen, Langberg et al. 2009).  However Paulsen and collegues report that after NSAID 
administration there was no significant differences in satellite cell number after exercise 
(Paulsen, Egner et al. 2010).  The conflicting reports in the literature deserve further 
attention.  
 
Protein synthesis is a crucial metabolic process to maintain mass and repair damaged 
muscle.  While there is evidence alluding to NSAID administration and a connection with 
adverse effects on muscle regeneration and growth after mechanical loading in both animal 
and human models (Soltow, Betters et al. 2006, Mikkelsen, Langberg et al. 2009, Novak, 
Billich et al. 2009), it has been reported that after three months of resistance training 
NSAIDs did not influence protein synthesis in elderly subjects (Petersen, Miller et al. 
2011).  Also observed in a recent human study was a positive effect of ibuprofen on muscle 
growth in healthy elderly individuals (Trappe, Carroll et al. 2011), which is further 
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highlighted by an animal model demonstrating that ibuprofen protected against loss of 
muscle mass in inflamed tissue of old rats compared to controls (Rieu, Magne et al. 2009).  
Furthermore studies investigating the role of NSAIDS on cancer cachexia and sarcopenia, 
suggest muscle mass is preserved when NSAIDs are administered (Sartorelli and Fulco 
2004, Beyer, Mets et al. 2012, Schiaffino, Dyar et al. 2013).  The literature is far from 
consistent, however it would seem that there is a greater volume of evidence suggesting 
that there may be a negative effect of NSAIDS on cellular activity in regards to 
regeneration opposed to a beneficial effect (Mackey, Mikkelsen et al. 2012).  However 
when examining an adverse effect of NSAIDs on muscle growth, the evidence is sparse. 
Although the use of NSAIDs may alleviate the bodies’ inflammatory response, dietary 
habits may also attenuate key mediators of inflammation (Esposito and Giugliano 2006, 
Richard, Couture et al. 2013).  In fact naturally occurring anti-inflammatory agents in foods, 
such as oleocanthal, are of considerable interest due to the putative health promoting 
benefits they deliver.   
 
1.7 Summary and Significance of Research 
The need to identify naturally occurring NSAIDs is of importance due to the risks 
associated with long term NSAID use such as damage to gastrointestinal mucosa.  Also to 
be considered is some evidence alluding to adverse effects of NSAIDs on muscle 
regeneration.  Therefore a risk- benefit ratio should be considered when using these 
synthetic drugs and naturally occurring NSAIDs such as oleocanthal could be a beneficial 
substitution.  Populations residing along the Mediterranean and whom consume a 
traditional Mediterranean diet with VOO as the principle source of dietary fat, enjoy a 
lower incidence of chronic inflammatory disease and this can be linked back to the 
healthful and anti-inflammatory properties of the phenolic compounds such as oleocanthal.    
 
Oleocanthal is a naturally occurring NSAID that is homogeneous to Ibuprofen, therefore it 
is of interest to compare these two compounds and their effects on skeletal muscle 
regeneration and growth and also inflammation in skeletal muscle cells.  Further to that, as 
both oleocanthal and ibuprofen target the same sensory receptor, the TRPA-1 receptor, and 
Chapter One – Literature Review 
________________________________________________________________________________________________ 
 
19 
 
based on the premise that there may be a link between the sensory (pertaining to the senses) 
and the systemic system (pertaining to the body), the objective of this thesis is to determine 
if such a link differentiates the effects that oleocanthal and ibuprofen have on regeneration 
and growth processes and anti-inflammatory actions in cell lines derived from human 
participants both sensitive and insensitive to the throat irritation derived from these 
compounds.  To date oleocanthal has been proven to be an effective pharmacological agent 
in several in vitro models of disease ranging from cancer to arthritis.  This thesis is both 
significant and novel as it evaluates the relationship between the natural NSAID 
oleocanthal and its synthetic counterpart ibuprofen both perceptually and also within the 
realms of skeletal muscle health.  Further to that we endevour to determine if there is a link 
between the sensory and pharmacological actions of oleocanthal in vitro; paving the way 
for a future market promoting naturally occurring NSAID. 
 
1.8 Aims 
The overarching aim is to determine the population variability in the oropharyngeal irritation 
of oleocanthal, and to determine if oropharyngeal sensitivity is related to the anti-
inflammatory actions and muscle regeneration and growth 
 
The objectives of this research are:  
Study 1.  To use intensity scaling to measure the oropharyngeal irritation elicited by VOO 
in a population sample.  To identify individuals who are hypersensitive (highly sensitive) 
and hyposensitive (highly insensitive) to oleocanthal (in VOO) for participation in study. 
To assess whether the irritant properties of oleocanthal is correlated with perceived 
intensity of the bitter compound PROP, and to assess if sensitivity to both compounds is 
related to dietary intake.   
  
Study 2.  To optimize the methodology for study 3 the compounds oleocanthal and 
ibuprofen will be used to determine their effects on myoblast proliferation, differentiation, 
protein synthesis and degradation, using mouse muscle cells.  Furthermore Oleocanthal 
and ibuprofen will also be used as a pretreatment to determine their effects on the mRNA 
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expression of TNFα, iNOS and IL-6 in C2C12 myotubes.  Proteins involved in the mTOR 
signaling pathway will also be measured.  The optimization of methodology will 
determine the methodology used for study 3. 
 
Study 3.  Muscle biopsies from 3 hypersensitive (highly sensitive) and 3 hyposensitive 
(highly insensitive) individuals (study 1) will be taken and levels of TRPA-1 mRNA 
expression in muscle cells will be determined.  The effects that oleocanthal and ibuprofen 
have on protein synthesis and degradation will be measured as will the effects on mRNA 
expression of LPS induced TNFα, IL-6, IL-8, and MCP-1 and TRPA-1. 
 
It was hypothesised that: 
 
 
1. There will be large variation in perceived perception in the throat irritation 
elicited by VOO containing oleocanthal and participants who have no 
irritation, or minor oropharyngeal irritation will be classified as hyposensitive, 
while those who have extreme oropharyngeal irritation will be classified as 
hypersensitive.  These participants will be invited to give a muscle biopsy for 
study 3.  We hypothesise that there will be a relationship between the 
perceived oropharyngeal irritation of oleocanthal, the bitterness of PROP, and 
dietary intake. 
2. Oleocanthal will act as an anti-inflammatory compound and will attenuate LPS 
induced iNOS, TNFD, and IL-6 mRNA expression in a similar manner to 
ibuprofen in C2C12 myotubes.  Oleocanthal will increase proliferation, 
differentiation and protein synthesis and decrease protein degradation in 
C2C12 mouse myotubes when compared to ibuprofen.  
3. Oleocanthal will differentially increase proliferation and protein synthesis and 
decrease protein degradation in cell lines derived from hypersensitive 
phenotypes compared to hyposensitive phenotypes.  Oleocanthal will exhibit 
anti-inflammatory actions and attenuate LPS induced, TNFD, IL-6 and IL-8, 
and MCP-1 mRNA expression in cell lines derived from hypersensitive 
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phenotypes compared to hyposensitive phenotypes.  This attenuation will also 
correlate with TRPA-1 mRNA expression. 
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Chapter Two: 
Methodology 
 
This chapter encompasses an overall methodology for the sensory component 
of this thesis contained in chapter 3    
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2 Methodology 
 
The following chapter will highlight the key methods used in this research to determine 
variability in perceived intensity of the irritation unique to oleocanthal ingestion.  The 
research design and recruitment criteria will be given for all the sensory research in this 
thesis, with the molecular methodology for later studies presented in each relevant chapter.  
2.1  Sensory screening and Oleocanthal identification 
2.1.1 Study Participants 
Study participants Subjects (n=168, aged 18-70, male n=46) and females (n=122) were 
recruited from Deakin University and surrounding suburbs.   
2.1.2 Dietary intake and anthropometry 
Data from the 4-day food diary included quantity brand of food, time meal was eaten, and 
preparation and cooking method.  Subjects were asked to, where possible, weigh the foods 
they consumed (subjects used their own scales), use standard metric measuring cups, or 
common serving sizes.  Dietary intake analysis was conducted using Foodworks nutritional 
software (Xyris, Brisbane, Australia, 2007).  Daily total energy, carbohydrate, protein, and 
fat intake was estimated to assess a possible association between taste sensitivity and 
dietary intake.  Intake of specific vegetables (spinach, broccoli, cabbage) was assessed to 
determine if there was an association between PROP sensitivity and intake of these 
vegetables.  Olive and olive oil intake was also estimated to determine if there was a 
relationship between oleocanthal sensitivity and intake of these foods containing 
oleocanthal.  Height was measured in cm on a stadiometer (Seca, Birmingham United 
Kingdom) and weight was measured in kg (Tanita BF-522, Arlington Heights, Illinois, 
USA). 
2.1.3 Taste Assays 
On the day of testing subjects attended the sensory laboratory at Deakin University on one 
occasion.  Subjects were trained in the use of the general Labelled Magnitude Scale 
(gLMS) (Green, Dalton et al. 1996, Bartoshuk, Duffy et al. 2004).   Because of the 
genetically determined individual differences in the way we perceive taste stimuli it is 
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simple to measure differences in perceived intensity of taste or chemesthetic stimuli within 
individuals, but far more difficult across groups of individuals (Bartoshuk 2000, Bartoshuk, 
Duffy et al. 2004).  The gLMS is a labelled scale of perceived sensation intensity to derive 
ratio level data similar to magnitude estimation data and contains descriptors ranging from 
barely detectable= 1.5, weak= 6, moderate= 17, strong= 35, very strong= 52 and the 
strongest imaginable sensation of any kind=100 (figure 2.1).  Only the descriptors are 
visible to the subject while the researcher receives numerical data from the scale.  Subjects 
were familiarised with the scale and given hypothetical examples corresponding to each 
descriptor on the scale.  For example subjects rated with the gLMS the intensity of the 
following remembered or imaginary taste sensations:  The warmth of lukewarm water, the 
coolness of an ice cold beverage, the bitterness of celery, the sourness of lemon, the 
burning sensation of consuming a hot whole chili and others.  If participants rated stimuli in 
the wrong region of the scale during training they were directed to the region on the scale 
where the sensation should occur and further hypothetical examples given until the subject  
 
 
 
Figure 2.1: General Labeled Magnitude Scal (gLMS) ranging from the strongest imaginable 
sensation of any kind to 100 to no sensation at 0. 
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fully understood scale usage.  Emphasis was given to the fact that the strongest imaginable 
sensation is representative of the strongest and most intense pain imaginable.   
Subjects then completed an intensity rating for oropharyngeal sensitivity to an olive oil 
determined to be highly irritating by the investigators, and as a control irritant subjects were 
asked to rate the intensity of mouth irritation elicited by CO2 in soda water.   
2.2 Oil Sample 
High-performance liquid chromatography (HPLC) analysis was used to quantify the 
concentration of oleocanthal in the oil sample (oil was supplied by Modern Olives 
Laboratory Service, Lara. Victoria. 2012 harvest) using methodology developed by 
Impellizzeri and Lin and modified by Cicerale and colleagues (Impellizzeri and Lin 2006, 
Cicerale, Breslin et al. 2009).  
2.2.1 Reagents and Standards 
Hexane and acetonitrile were purchased from Rowe Scientific (Hallam, Australia).  
Methanol water (HPLC grade) (1/1, v/v) was used to dissolve extract residue.  A stock 
solution of 3, 5- dimethoxyphenol (Aldrich, U.S) was used as an internal standard and this 
has been found to be a suitable compound for the quantification of oleocanthal elsewhere 
(Impellizzeri and Lin 2006).  The internal standard was added to the VOO (10g) at a 
concentration of 500μg/g and oleocanthal concentration was expressed as 3.5 
dimethoxyphenol (ISTD) equivalents.   
 
2.2.2 Oleocanthal extraction 
Samples were prepared and analysed in triplicate.  Oleocanthal was extracted from the oil 
sample by liquid-liquid extraction.  A VOO sample (10g) was treated with hexane (10ml) 
and vortexed (1min) to mix.  Acetonitrile (50ml) was then added to the sample and 
vortexed (1min) to mix.  The sample was centrifuged for 4000 rpm for 5 min to separate 
the oil from the solvent phase.  The solvent extract was transferred to an evaporator flask 
and the solvent was removed by rotary evaporation (In Vitro Technologies, Noble Park 
North, Australia) at 45° and 200mbar.  Methanol/water (1ml) was used to dissolve the 
extract and hexane was added to the extract to ensure removal of any remaining oil.  The 
sample was centrifuged (4000rpm for 2min) for separation and the remaining methanol 
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water phase was collected for analysis.  
 
2.2.3 HPLC Analysis 
All analytical separations were performed using a 1200 series HPLC system with solvent 
degasser, quaternary pump, auto sampler and diode array detector set to 278nm (Aglient 
Technologies, Blackburn, Australia).  An Apollo RP-C18 column (250mm x4.6 mm ID, 
5μm: Grace Davidson, Baulkham Hills, Australia) was used for all separations.  
Temperature was constant at 25°C.  The following eluting solvents were used A: methanol, 
B: acetonitrile, C: water.  The flow rate was 1ml/min and the injection volume was 20μl.  A 
6210 MSDTOF mass spectrometer (Aglient Technologies, Blackburn, Australia) was used 
to identify oleocanthal using the following: nebuliser gas, drying gas, nitrogen (15 psi), 
capillary voltage 4.0 kV, vaporiser temperature, 350°C, cone voltage, 60V.  
 
2.3 Screening for taste sensitivity 
2.3.1 Taste sensitivity to oleocanthal 
The method for the oleocanthal taste assay was developed by Beauchamp and colleagues 
(Beauchamp, Keast et al. 2005) and modified accordingly by Cicerale and colleagues 
(Cicerale, Conlan et al. 2009).  Subjects rinsed their mouths with filtered water (8 μm 
particulate filter with an activated charcoal filter, Dura®) at least 3 times over a 2-min 
period before commencement of testing.   Each subject sampled and rated (using the 
gLMS) VOO for oleocanthal irritation and soda water for CO2 irritation in the oropharynx 
in duplicate.  In the session, 2 VOO and 2 soda water samples were presented in a 
randomized order with an interstimulus interval of 1 min between samples. 
  Subjects were given 5ml aliquots of VOO containing oleocanthal (62mg/kg)  and asked to 
place the oil in their mouths and tilt their head back to allow the oil to drizzle down the 
back of their throat.  Subjects were asked to keep the oil at the back of the throat for ׽5 s, 
then swallow the sample in 2 stages, and rate the peak intensity of irritation after 20 s on 
the gLMS scale.  The irritation induced by CO2 in soda water was used as a control.  
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2.3.2 Taste sensitivity to PROP 
Filter papers containing the the bitter tasting compound 6-n-propylthiouracil (PROP) were 
prepared in accordance to the methods adapted from Zhao and colleagues (Haddad, 
Zaldivar et al. 2005).  Filter paper disks (1.5x 1.5 cm2) were prepared and submerged in a 
50mM/L PROP solution.  The paper discs were then oven dried and wrapped individually 
in plastic film.  Briefly subjects were familiarized with the gLMS scale, and were given 
hypothetical stimuli to rate intensity on the scale.  Subjects were then given a paper disc 
containing PROP and asked to place the paper on their tongue for 5 sec.  Subjects were 
then asked to rate the perceived intensity of bitterness on the gLMS scale.  
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Chapter Three: 
Variation in sensitivity to the Oropharyngeal 
irritation evoked by Oleocanthal 
 
Chapter three presents the results from study 1 of this thesis focusing on the individual 
variation in sensitivity to the oropharyngeal irritation of oleocanthal and the classification 
of those hypersensitive (extremely sensitive) and those hyposensitive (extremely 
insensitive) to the irritant properties.  This chapter also contains a study investigating the 
sensory perception of oleocanthal and its relationship with a bitter tasting compound PROP 
and investigates if sensitivity to these compounds are related to diet 
To keep both sections of chapter 3 distinct this chapter has been split into two sections, one 
section focusing on sensory screening for sensitivity to oleocanthal, and the second section 
focusing on a potential relationship between perception of oleocanthal irritation and PROP 
bitterness, and dietary intake. 
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3 Variation in sensitivity to the oropharyngeal 
irritation of oleocanthal 
 
3.1 Abstract 
Oleocanthal, a phenolic compound, has been identified as the sole oropharyngeal irritant in 
VOO.  The irritation and pungency accompanying VOO ingestion is a unique sensory 
experience shared only with the NSAID ibuprofen.  Sensory response to compounds in 
foods is a very individual experience, and as with most chemicals in foods, oleocanthal has 
been reported to evoke variable oropharyngeal irritation.  As there have been suggestions of 
a link between the sensory (the taste and chemesthetic response) and the systemic (the 
pharmacological activities of the compound in the body), it is of interest to investigate this 
link further.  Additionally an association between the oral sensitivity to food chemicals and 
dietary intake has been suggested, and may have implications for nutritional health.  We 
therefore aim to screen sensitivity to the oropharyngeal irritation of oleocanthal, to 
categorise participants as hypersensitive (extremely sensitive) or hyposensitive (extremely 
insensitive), and ask hypersensitive and hyposensitive individuals to participate in study 3; 
Investigating individual differences in perceptual sensitivity to oleocanthal and a link to 
differential effects from oleocanthal treatment in muscle.  We further aim to determine the 
magnitude of individual variation in oral sensitivity to irritation from oleocanthal, and 
bitterness from 6- n-propylthiouracil (PROP) and determine if a relationship exists between 
sensitivity to these compounds and dietary intake.  Participants (n= 168, male n= 46, female 
n=122, 23.2±2.18 years, body mass index 22.6±1.27kg/m2) took part in the initial screening 
of irritation to oleocanthal to identify hypersensitive and hyposensitive individuals to take 
part in study 3.  From this sample 87 participants (females n= 74, males n=13, 20.2±3.78 
years, body mass index 21.9±0.6kg/m2) rated the intensity of oropharyngeal irritation of 
olive oil and the bitterness of PROP using a gLMS scale and participated in the dietary 
study.  Dietary intake was assessed by 4-day food record.  There was large variability in the 
perceived intensity of irritation from olive oil (gLMS range: 1.70- 70.31) and three 
hypersensitive (highly sensitive) individuals and three hyposensitive (highly insensitive) 
individuals were identified to take part in study 3.   The intensity of irritation for olive oil 
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was not correlated with the percieved intensity of irritation from CO2 in soda water (P = 
0.77).  There was also large variation in the percieved bitterness of PROP (gLMS range: 
0.0-62.5) and there was no association between PROP sensitivity and oleocanthal irritation 
(p=0.71).  We report no correlation between total energy intake or macronutrient intake 
(range p=0.29-0.92) for oleocanthal, or PROP (p=0.31-0.53).  We did find a significant 
negative correlation between PROP sensitivity status and the intake of broccoli (p=<0.05).  
In the present study individual variation in sensitivity to the irritation of virgin olive oil or 
bitterness of PROP was not related to diet with the exception of PROP sensitivity and 
broccoli intake.  
 
Section one- Sensory screening 
3.2 Introduction 
Oleocanthal produces irritation in the oropharyngeal region and may be associated with 
discomfort upon ingestion of VOO.  Chemesthesis is often associated with uncomfortable 
responses such as burning, stinging and irritation and can be modulated by both thermal 
and tactile stimuli.  For example capsaicin contained in a hot chili will produce a more 
intense burning sensation whereas in a more temperate dish the burning sensation will be 
perceived as less intense (Green 1990).  Chemesthesis differs from the basic taste descriptors 
and olfaction in a number of ways because rather than only being conveyed by taste 
receptors on taste cells, it is a result of compounds contained in foods making their way to 
the sensitive nerve endings in the deep mucosal membranes of the mouth (Bennett and 
Hayes 2012, Ludy and Mattes 2012).   
Many foods elicit chemesthetic perceptions; a good example is virgin olive oil (VOO).  
VOO, a staple of the traditional Mediterranean diet has been recognized not only for its 
contribution to the health benefits accompanying adherence to this dietary regime, but also 
for its unique organoleptic characteristics (Cicerale, Breslin et al. 2009, Peyrot des 
Gachons, Uchida et al. 2011, Pérez, León et al. 2014).  The flavor of VOO is significantly 
different from other edible oils as it combines chemical responses such as pungency and 
irritation with taste and odor creating a distinct combination that is related to the preference 
of different oil cultivars (Bendini, Cerretani et al. 2007, Pérez, León et al. 2014).  The 
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distinctive sensory qualities of VOO are primarily a result of the phenolic components 
contained in the oil, in particular oleocanthal.   
 
The story of oleocnathal began in the late 90’s when Beauchamp and collegues were asked 
to assist in addressing the sensory displeasure associated with an ibuprofen based cold 
remedy.  They quickly realised that ibuprofen provokes an irritation that is isolated to the 
oropharyngeal region.  In 1998, at a conference involving the sensory evaluation of VOO, 
the researchers sampled a fresh batch of VOO and experienced that same spatial irritation 
in the oropharyngeal region that accompanied the ingestion of ibuprofen.  As a result the 
hypothesis was formulated that the compound in VOO that evokes the same stinging 
irritation as ibuprofen may also share anti-inflammatory properties, which we now know as 
fact.  Andrewes and colleagues later indicated that the phenolic decarboxy methyl 
ligstoside aglycone  produced the distinct throat irritation that is associated with VOO 
ingestion (Andrewes, Busch et al. 2003).  This was confirmed by Beauchamp and collegues 
and the compound was aptly named oleocanthal (oleo-throat, canth- sting and al- aldehyde) 
(Beauchamp, Keast et al. 2005).  It is now widely recognized that oleocanthal creates a 
distinct burning irritation in the oropharyngeal region that can be experienced with VOO 
ingestion  (Beauchamp, Keast et al. 2005, Cicerale, Breslin et al. 2009, Peyrot des Gachons, 
Uchida et al. 2011, Bennett and Hayes 2012).   
 
The idea that individuals live in their own sensory world has been communicated through 
the literature over decades (Bartoshuk 2000, Kim and Drayna 2005, Shigemura, Shirosaki 
et al. 2009) and variability in the perceived sensitivity of irritation of oleocanthal and bitter 
taste from compounds in foods have been noted amongst individuals (Prutkin, Duffy et al. , 
Duffy and Bartoshuk 2000, Cicerale, Breslin et al. 2009).  For instance some chemicals, 
classed as oral irritants derived from foods are perceived as intense, a hot chilli is well 
tolerated by some individuals whereas others cannot endure the chemesthetic response.  
The individual variation in perception of bitter taste is presumably a result of individual 
genetic factors (Keller, Steinmann et al. 2002, Tepper and Ullrich 2002, Bufe, Breslin et al. 
2005, Dinehart, Hayes et al. 2006, Hayes, Bartoshuk et al. 2008, Duffy, Hayes et al. 2010, 
Hayes, Wallace et al. 2011).  It is logical to assume that this applies to large variation in 
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oleocanthal sensitivity as well, with the recent discovery that oleocanthal selectively 
activates the human nociceptor, transient receptor potential cation channel, member A1 
(TRPA1) in HEK 293 cells (Peyrot des Gachons, Uchida et al. 2011).  Beauchamp and 
collegues along with other researchers have investigated the affinity of oleocanthal and 
ibuprofen with the TRPA-1 channel protein which responds to chemicals and temperature 
and is located in abundance in the upper throat and nose.  This explains the localized throat 
sensation arising from oleocanthal and ibuprofen ingestion (Beauchamp, Keast et al. 2005, 
Peyrot des Gachons, Uchida et al. 2011).  It is therefore also to be expected that the genetic 
variance in distribution of TRPA1 receptor levels across individuals is reason to why one 
individual may find the intensity of throat irritation from oleocanthal severe whereas 
another may find it mild or non-existent (Cicerale, Breslin et al. 2009).  
 
Because of the genetically determined individual differences in the way we perceive taste 
stimuli it is simple to measure differences in perceived intensity of taste or chemesthetic 
stimuli within individuals, but far more difficult across groups of individuals (Bartoshuk 
2000, Bartoshuk, Duffy et al. 2004).  Fast and colleagues (2002) discuss this difficulty in 
terms of the ceiling effect that is common in most scales and which can significantly reduce 
the intensity of the individual sensory experience (Katharine Fast, Bartoshuk et al. 2002).  
To address this Green and colleagues (Green, Shaffer et al. 1993) developed The Labeled 
Magnitude Scale (LMS) which consists of intensity adjectives spaced at empirically 
determined distance.  The LMS was then stretched to enable ‘the strongest imaginable 
sensation of any kind’ to be placed at the top of the scale increasing the validity of across 
group comparisons to give us the gLMS scale (Bartoshuk, Fast et al. 2005) ( see figure 2.1, 
chapter 2).  Of importance is ‘the strongest imaginable’ descriptor avoids a ceiling effect 
(Prutkin, Duffy et al. , Bartoshuk, Duffy et al. 2003).  For instance as the sensory stimuli 
that each individual receives will never reach the individual perception of the ‘strongest 
imaginable sensation of any kind’ the ceiling is not reached.  Sensory experts have 
encouraged the use of gLMS for several years due to the superior data quality and the 
ability of the scale to differentiate between perceived sensations amongst those with 
differing taste sensitivities.  Cicerale and colleagues used this approach to determine the 
variability in perceived intensity of the oropharyngeal irritation of oleocanthal (Cicerale, 
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Breslin et al. 2009) as have other researchers (Bennett and Hayes 2012).  Whilst individual 
variation in the perceived intensity of bitterness evoked by PROP has been demonstrated 
many times (Dinehart, Hayes et al. 2006, Hayes, Wallace et al. 2011), the level of 
individual difference in perceived intensity of throat irritation produced by oleocanthal 
needs to be further explored.  Therefore the aim of this chapter is to assess the variation in 
the perceived intensity of oleocanthal adding to previous research and to identify those 
highly sensitive and those highly insensitive to take part in study 3 of this thesis linking the 
sensory aspects of oleocanthal with its pharmacological actions. 
3.3 Materials and Methods 
3.3.1 Subjects 
Participants (n=168, aged 18-70, male n=46 and females n=122) were recruited from 
Deakin University and surrounding suburbs.  Flyers were distributed via letterbox drop and 
were also placed at various locations around Deakin University.  This study was conducted 
according to the guidelines laid down in the Declaration of Helsinki and all procedures 
involving human subjects/patients were approved by the Deakin University Human 
Research Ethics Committee and all participants provided written informed consent prior to 
participation. Participants attended one sensory session at Deakin University sensory 
laboratory. 
Please refer to chapter 2.1.2 and 2.3.1 for methods 
3.3.2 Statistical analysis 
Statistical analysis was performed on SPSS statistical software VER 12.0 (SPSS, Inc, 
Chicago, IL, USA). Spearman’s correlation was used to determine correlations between 
gLMS ratings to the irritation from oleocanthal in VOO and the irritation from CO2 in soda 
water as the rating frequency of irritant intensity of CO2 was not displayed in a normal 
distribution.  Data from the gLMS was organized into tertiles with frequency reported.  A 
one way ANOVA was used to detect differences in energy and macronutrient intake 
between hypo (low sensitive, those in the bottom of tertile 1) and hyper (high sensitive, 
those in the top of tertile 3) individuals and independent samples t-tests were used to detect 
differences in BMI and nutrient intake.  Fishers Exact Test was used to determine 
associations between oleocanthal and PROP sensitivity.  To investigate if a correlation 
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exists between oleocanthal sensitivity, total energy intake, and macronutrient intake, or 
PROP sensitivity, total energy intake, and macronutrient intake Pearsons product moment 
correlations were applied.  Data is presented as mean±SD and p values <0.05 are 
considered significant.    
3.4 Results 
3.4.1 Subjects 
Full data was obtained from 168 participants (male n=46, female n=122, 23.2±2.18 years, 
BMI 22.6±1.27kg/m2). 
3.4.2 Oral sensitivity to oleocanthal in VOO and CO2 in soda water 
The mean perceived irritation from oleocanthal was 29.52 ± 1.04 gLMS and there was large 
variability in perceived intensity of irritation from oleocanthal (range 1.70 – 70.31) (figure 
3.1a). The mean range of oleocanthal ratings was greater than the irritation reported from of 
CO2 in soda water (mean 3.11 ± 0.23, range 0.00- 19.60).  Figure 3.1 displays histograms 
comparing ratings from oleocanthal and soda water on a gLMS scale. 
 
 
 
 
 
 
 
 
 
Figure 3.1.a:                                                                                                     Figure 3.1.b 
Figure 3.1 Histograms of rating frequency (gLMS) of irritant intensity of oleocanthal (figure 
3.1a) and CO2 (figure 3.1b).  The x axis represents the average irritation on the gLMS by an 
individual subject. The y axis represents the number of subjects. Each bar represents the 
number of people who rated the irritation at the specified intensity range. 
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There was no correlation between perceived intensity of oleocanthal irritation and soda 
water irritation (r = 0.02, P = 0.80), demonstrating that the mechanism of irritation between 
these irritants is independent.  After organizing the data into tertiles we report that the 
mean±SEM rating of those in the lowest tertile (those rating oleocanthal as low irritating on 
the gLMS scale) was 14.35±0.8 with a range from 1.70-21.93.  The mean±SEM of those in 
the middle tertile was 29.8±0.5 in a range from 22.34-35.20 and in the highest tertile (those 
rating oleocanthal as highly irritating on the gLMS) was 44.4±0.97 within a range of 35.98- 
70.71 (figure 3.2).  Participants that were classified as insensitive were selected from the 
lowest tertile and those classified as sensitive were selected from the highest tertile. CO2 
tertiles were plotted (figure 3.3) for comparison.  There was no relationship between CO2 
and oleocanthal tertile groups (r-0.06, p=0.44). 
 
 
 
 
 
 
 
 
 
 
 
 
 
                     
 
Figure 3.2 Oleocanthal gLMS ratings organized into tertiles. Tertile 1 contains the lowest 
ratings (range from 1.70-21.93).  Tertile 2 contains the mid range ratings (range from 22.34-
35.20) and tertile 3 contains the highest ratings of irritation (range 35.98-70.71). The x axis 
represents the average irritation on the gLMS by an individual subject. The y axis represents 
data grouped in tertiles. 
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Figure 3.3 CO2 gLMS ratings organized into tertiles. Tertile 1 contains the lowest 
ratings (range from 0.00-6.53).  Tertile 2 contains the mid range ratings (range from 
6.53-13.03) and tertile 3 contains the highest ratings of irritation (range 13.06-19-59). 
The x axis represents the average irritation on the gLMS by an individual subject. The 
y axis represents data grouped in tertiles. 
  
 
3.5 Discussion 
The wide variation in perceived intensity of the irritation produced by oleocanthal reported 
here has been noted elsewhere (Beauchamp, Keast et al. 2005, Cicerale, Breslin et al. 2009, 
Bennett and Hayes 2012).  This is logical as the individual perception of irritation varies in 
accordance with the set of alleles coding for receptor proteins, taste and smell that each 
individual possesses.   The unimodal distribution of oleocanthal sensitivity on the bell shaped 
curve displays both extremely insensitive (gLMS 1.70) and sensitive individuals (gLMS 
70.31) and as expected this methodology avoided the ceiling effect observed with other 
intensity scaling measures.  The variation in perception of oleocanthal amongst the 168 
participants in this study may be related directly to the quantity of TRPA-1 receptors in the 
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oropharyngeal region as reported by des Gachons and collegues (Peyrot des Gachons, Uchida 
et al. 2011).  This variation has also been reported with other oral stimuli such as 6-n-
propylthiouracil (PROP) and phenylthiocarbamide (PTC) bitterness (Bufe, Breslin et al. 2005, 
Dinehart, Hayes et al. 2006, Hansen, Reed et al. 2006, Hayes, Wallace et al. 2011).  There 
appears to be no idiosyncratic use of the gLMS scale in this study as there is no correlation 
between ratings of oleocanthal irritation and the irritation of CO2 in soda water (Cicerale, 
Breslin et al. 2009).  Building on previous studies from our lab and others, this large inter-
individual variation in sensitivity to oleocanthal, combined with a non-correlation with 
reported CO2 intensity, indicates that the oropharyngeal irritation of oleocanthal is 
independent of another chemesthetic stimulus, CO2.  This suggests that sensitivity or 
insensitivity to the throat irritation of oleocanthal is indicative of differing TRPA-1 receptor 
levels and that oleocanthal specifically targets TRPA-1 the oropharynx region (Peyrot des 
Gachons, Uchida et al. 2011, Bennett and Hayes 2012).  
 
As previously observed in the work of Cicerale and colleagues the distribution of perceived 
intensity to the irritation of oleocanthal follows as bell shaped curve with few participants 
reporting high perceived intensity and very few reporting very low (Cicerale, Breslin et al. 
2009).  This is expected as with all sensory systems individuals have different capabilities and 
responses.  In regards to bitter taste around 30% of the population do not detect bitterness from 
PROP compared with the majority that do perceive bitter, but at different intensities, with 
much variation.  This is due to allelic variation in a TAS2R gene, TAS2R-38 which is 
responsible for the ability to taste thiourea compounds such as PROP and PTC (Kim, 
Wooding et al. 2005, Hayes, Wallace et al. 2011).  Two common haplotypes result from 
TASR2-38, PAV, which is the dominant ‘taster’ haplotype and AVI, which is the ‘non-taster’ 
recessive haplotype (Bufe, Breslin et al. 2005, Kim, Wooding et al. 2005, Hayes, Bartoshuk et 
al. 2008).  While those who cannot taste PROP are homozygous for the AVI haplotype, there 
is variation in the perceived intensity of PROP bitterness for those with taster haplotype 
(PAV).  Some are classified as super-tasters while others medium tasters (Hayes, Bartoshuk et 
al. 2008).  However allelic diversity in TAS2R-38  does not explain differences between those 
who are extremely sensitive to bitter taste and those who are classified as medium tasters and 
other factors need to be explored such as additional receptor involvement in bitter taste 
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perception (Hayes, Bartoshuk et al. 2008). Variation in TRPA-1 gene can alter pain perception 
(Kremeyer, Lopera et al. 2010).  There are no studies reporting genetic variation in the 
distribution of TRPA-1 receptor in the oropharynx, however there is a large number of coding 
region variants in TRPA-1 that may potentially produce the variability in oleocanthal irritation 
reported here and in other similar studies (NCBI. 2015).  
 
An interesting hypothesis introduced by Fischer the 1960’s is that the individual sensory 
response to a compound may be able to predict its function in the body.  Fischers inaugural 
study reported that taste sensitivity to the bitterness of sodium saccharinate, measured by 
Weber ratio, could predict the intensity of drug-effects from Psiocybin which is used to 
treat schizophrenia (Fischer, Griffin et al. 1965).  It may be then that those who are highly 
sensitive (hypersensitive) to the irritation evoked by oleocanthal in the oropharynx may be 
more receptive systemically to the anti-inflammatory properties of oleocanthal.  From this 
study three hypersensitive and three hyposensitive subjects have been identified and will be 
asked to return to give tissue samples and test this hypothesis in study 3 (see table 3.1).   
 It is of further interest to examine if there is a relationship between the perceived irritation 
of oleocanthal and dietary intake as this has been reported for those genetically predisposed 
to sensitivity to bitter taste (Duffy and Bartoshuk 2000, Keller, Steinmann et al. 2002, 
Yackinous and Guinard 2002, Basson, Bartoshuk et al. 2005, Duffy, Hayes et al. 2010).  
The next section of this study focuses on sensory responses i.e perceived intensity, to the 
irritation accompanying oleocanthal contained in VOO, and the bitterness produced by 
PROP placed on the tongue and a relationship to dietary intake. 
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Table 3.1: Ratings of perceived intensity of oleocanthal irritation (gLMS) for those classified 
as extremely sensitive and insensitive and who will be giving muscle tissue for study 3 
 
 
 
 
 
 
 
 
 
Section 2, study 1: Oleocanthal, PROP, and diet 
3.6 Relationship between diet and oral sensitivity status to prop, and 
olive oil   
3.6.1 Introduction 
The increasing awareness and prevalence of nutrition related disease such as diabetes and 
cardiovascular disease, has promoted the importance of understanding the drivers of food 
choice to the forefront of nutritional research (Duffy, Hayes et al. 2009, Cicerale, Riddell et 
al. 2012) (Bufe, Breslin et al. 2005, Hayes and Duffy 2008, Duffy, Hayes et al. 2009).  
How we perceive the sensory attributes of foods is unique as we each have our own world 
of flavour and this may impact what we choose to eat (Drewnowski 1997, Keller, 
Steinmann et al. 2002, Bartoshuk, Fast et al. 2005).  Indeed this is likely, as it is established 
that the sensory attributes of food (taste, smell, and chemesthetic sensations) play a role in 
food choice, and our sense of taste is one critical element within a range of factors that 
determine dietary preferences (Bolhuis, Lakemond et al. 2012, Hoppert, Mai et al. 2012) .   
 
insensitive 1 sensitive 1 
1.70 61.24 
insensitive 2 sensitive 2 
2.20 59.70 
insensitive 3 sensitive 3 
4.70 55.60 
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Bitter taste is believed to be an evolutionary defensive mechanism to protect animals from 
ingesting toxic substances and may be linked with dietary intake (Beckett, Martin et al. 
2014).  The most widely studied compound in taste research is the bitter compound PROP 
(Hayes and Duffy 2008, Tepper, Neilland et al. 2011).  PROP is not found in the food 
supply, however many vegetables, such as cauliflower, broccoli and spinach contain 
glucosinolates which have a chemical moeity (N-C=S group) similar to PROP.  PROP has 
been shown to evoke large individual variation in perceived bitterness and sensitivity and 
has been reported to influence the intake of cruciferous vegetables (Duffy and Bartoshuk 
2000, Yackinous and Guinard 2002, Tepper, Neilland et al. 2011, Sharafi, Hayes et al. 
2013) and also citrus fruit (Catanzaro, Chesbro et al. 2013).  The ingestion of cruciferous 
vegetables such as broccoli has been shown to have anti- carcinogenic properties, therefore 
a reduced sensitivity to bitter taste may be a result of evolutionary influences to reduce 
cancer risk, without an aversive taste experience (Basson, Bartoshuk et al. 2005, Meyerhof, 
Batram et al. 2010).  Alternatively increased sensitivity to bitter taste may ensure aversive 
responses so to deter ingestion (Anliker, Bartoshuk et al. 1991, Duffy, Hayes et al. 2010, 
Feeney, O'Brien et al. 2011, Sharafi, Hayes et al. 2013).   For example goitrogens, 
associated with vegetables containing glucosinolate, may interfere with thyroid function 
(Duffy, Hayes et al. 2010, Clark 2014).  Therefore increased sensitivity to PROP and 
similar bitter tasting compounds may be a protective mechanism for those at risk of thyroid 
related health issues (Clark 2014).  It should be noted that evidence linking PROP 
sensitivity and dietary intake is thus far conflicting and inconclusive.   
           
Like bitter taste, the pungency or oral irritation from compounds in foods is believed to act 
as a protective defense against the consumption of toxins in foods (Des Gachons, 
Beauchamp et al. 2009).  Furthermore the pungency and oral irritation from foods may also 
play a role in dietary intake, as these taste qualities can be viewed as positive attributes 
(Peyrot des Gachons, Uchida et al. 2011) .  Phenolic compounds are the minor component 
of VOO that are largely associated with the health benefits of the oil (Cicerale, Lucas et al. 
2010, Lucas, Cicerale et al. 2011, Cicerale, Lucas et al. 2012, Casaburi, Puoci et al. 2013, 
Amiot 2014, Parkinson and Keast 2014).  From a sensorial viewpoint, the phenolic 
compound oleocanthal is important as it evokes the distinct and somewhat pungent and 
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irritant characteristic, which is associated with VOO intake (Beauchamp, Keast et al. 2005, 
Cicerale, Breslin et al. 2009, Peyrot des Gachons, Uchida et al. 2011, Bennett and Hayes 
2012).  As demonstrated in the previous section of this chapter there is large inter 
individual differences in the sensory perception of the oropharyngeal irritation produced 
from oleocanthal. 
 
Specifically the aim of this study is to build on the existing taste status and food intake 
literature with the hypothesis that there may be a link between the perceived intensity of 
irritation to a VOO containing oleocanthal, and the perceived bitterness of PROP.  This 
study also endeavored to determine if sensitivity is associated with dietary intake.  A 
potential relationship should be considered as differences in taste sensitivity may influence, 
or be influenced by dietary behavior, which in turn may influence nutritional status.   
3.7 Materials and Methods 
3.7.1 Screening for dietary study 
Study participants 87 participants, male (n=13) and female (n=74) participants from Deakin 
University took part in the dietary study.  
3.7.2 Taste Assays 
On the day of testing subjects attended the sensory laboratory at Deakin University on one 
occasion.  Subjects were trained in the use of the general Labelled Magnitude Scale 
(gLMS) (Green, Dalton et al. 1996, Bartoshuk, Duffy et al. 2004) (see 2.1.2 ) 
 Subjects then completed the following tests. 1: An intensity rating for oropharyngeal 
sensitivity to oleocanthal.  2: An intensity rating for taste sensitivity to the bitter compound 
PROP.  Subjects were seated in computerised, partitioned sensory booths at Deakin 
University sensory laboratory for all testing.  Seven days prior to the testing session 
subjects were given a four-day food diary (household measures) to complete. 
Please refer to methodology in chapter 2 (2.12 and 2.31)  
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3.8 Results 
3.8.1 Subjects   
Full data was obtained from 87 participants, (74 female, 13 male) 20.2±3.78 years, body 
mass index 21.9±0.6kg/m   
3.8.2 Oral sensitivity to oleocanthal 
The mean perceived irritation from oleocanthal was 31.70 ± 12.34 gLMS and there was 
large variability in perceived intensity of irritation from oleocanthal (range 4.26 - 57.15) 
(figure 3.3). 
3.8.3 Oral sensitivity to PROP 
The mean perceived bitterness was 27.41 ± 17.0 gLMS and there was large variability in 
perceived intensity of bitterness from PROP (range 0.0- 62.52) (figure 3.4). 
 
 
Figure 3.4 Variability in sensitivity to oleocanthal (gLMS mean: 31.7, SD: 12.35, range: 4.26-
57.15). The x axis represents the average irritation on the gLMS by an individual subject. The 
y axis represents the number of subjects. Each bar represents the number of people who rated 
the irritation at the specified intensity range. 
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Figure 3.5 Variability to PROP (gLMS mean: 27.4, SD: 16.9, range: 0.0-62.52 ). The x axis 
represents the average irritation on the gLMS by an individual subject. The y axis represents 
the number of subjects. Each bar represents the number of people who rated the irritation at 
the specified intensity range. 
 
3.8.4 Relationship between taste sensitivity to oleocanthal and PROP 
Fishers Exact Test indicated no evidence of an association.  There was no correlation 
between sensitivity to oleocanthal and PROP (r=-0.04, p= 0.71).  
3.8.5 Relationship between taste sensitivity to oleocanthal and PROP, and total 
dietary intake 
There were no associations between sensitivity to the perceived irritation of oleocanthal and 
total energy intake (r=0.13, p=0.29), carbohydrate intake (r=0.12, p=0.92), protein intake 
(r=-0.11, p=0.37) or fat intake (r=0.14, p= 0.22).  Similarly, there was no evidence of a 
relationship between sensitivity to the perceived intensity of bitterness of PROP and total 
energy intake (r=-0.08, p=0.46), carbohydrate intake (r=0.12, p=0.31), protein intake 
(r=0.12, p=0.32), or fat intake (r=-0.08, p=0.53).   
There was no evidence of association between sensitivity to the perceived irritation of 
oleocanthal and the intake of olives (r=0.05, p=0.66), or olive oil (r=0.02, p=0.85).  There 
was no correlation between sensitivity to the perceived intensity of bitterness of PROP and 
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cabbage intake (r=-0.04, p=0.75), PROP and cauliflower intake (r=0.09, p=0.45) or PROP 
and spinach intake (r= 0.19, p=0.10).  However there was a significant negative weak 
association between PROP sensitivity and the intake of broccoli (r=-0.24, p=0.05). Table 
3.2 and 3.3 displays differences in total energy and macronutrient intake between 
oleocanthal and PROP sensitive and insensitive participants. 
Table 3.2: Differences in total kilojoule and fat intake oleocanthal sensitive and insensitive 
participants 
Mean+SEM Oleocanthal Sensitive (n=50) Oleocanathal Insensitive (n=37) 
Energy 10410.51±488.12 9943.87±585.93 
Fat total (g) 95.41±5.88 86.65±7.19 
Fat sat (g) 34.65±3.83 31.01±2.76 
Fat poly (g) 14.19±1.36 14.53±0.74 
Fat mono (g) 
CHO 
Protein 
38.91±2.83 
287.02±14.80 
116.28±6.14 
34.22±3.16 
258.67±12.43 
112.91±8.25 
 
 
 
Table 3.3: Differences in total kilojoule and fat intake PROP sensitive and insensitive 
participants 
Mean+SEM PROP Sensitive (n=38) PROP Insensitive (n=49) 
Energy 9857.19±596.70 10485.49±478.40 
Fat total (g) 87.44±7.36 95.00±5.76 
Fat sat (g) 30.86±2.98 34.84±2.29 
Fat poly (g) 14.26±1.13 14.39±0.74 
Fat mono (g) 
CHO 
Protein 
35.45±3.29 
290.39±15.65 
123.59±8.95 
38.08±2.77 
263.65±13.10 
108.28±5.32 
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3.9 Discussion 
This study found no evidence of an association between perceived sensitivity to two 
compounds, oleocanthal and PROP.  We did find a large variability in individual perceived 
intensity of bitterness of PROP ,which was distinctly bimodal, and also large variability in 
oral irritation from oleocanthal, which is consistent with results from prior studies 
(Cicerale, Breslin et al. 2009, Bennett and Hayes 2012).    
 
3.9.1 Sensitivity to PROP and dietary intake 
An investigation focusing on a possible association between irritants in food such as 
oleocanthal, and a bitter tasting compound such as PROP has not been previously 
undertaken.  Therefore this research is novel and is the first to show a lack of association 
between two often perceived unpleasant taste sensations.   
This study observed a negative correlation between sensitivity to PROP and the dietary 
intake of broccoli supporting another study (Duffy and Bartoshuk 2000).  Broccoli is a 
nutrient rich food and is distinctly bitter to some individuals.  Early in human history the 
ability to seek out nutrient rich foods whilst avoiding toxic foods was important for survival 
and the genetic distribution of bitter taste receptors may have evolved as a physiological 
survival tool (Feeney, O'Brien et al. 2011).  Decreased sensitivity to bitter taste may have 
developed to encourage the intake of vegetables such as broccoli, due to the health 
promoting, cancer fighting properties that these foods possess (Hayes and Duffy 2008, 
Feeney, O'Brien et al. 2011).  Alternatively increased bitter taste sensitivity may ensure 
aversive responses to deter ingestion, as vegetables containing glucosinolate such as 
broccoli have been shown to interfere with thyroid function (Hayes and Duffy 2008).  We 
found no association between sensitivity to bitter taste elicited by PROP and total energy or 
macronutrient intake.   
 
Throughout the literature the bitter taste gene TAS2R38 has received significant attention 
as the gene responsible for variation in sensitivity to PROP and also phenylthiocarbamide 
(PTC).  As previously mentioned, rising from the TAS2R38 gene, 13 single-nucleotide 
polymorphisms (SNPs) have been recognized (Hayes, Bartoshuk et al. 2008).  Three of 
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these SNPs have resulted in three amino acid substitutions which give rise to two common 
haplotypes Ala-Val-Ile (AVI) which cannot perceive PROP bitterness, and Pro-Ala-Val 
(PAV) which can perceive PROP bitterness (Hayes, Bartoshuk et al. 2008).  Taste 
sensitivity to PROP and PTC are highly correlated reflecting their shared affinity to the 
TAS2R38 receptor (Bufe, Breslin et al. 2005), and this relationship is seen between 
oleocanthal and ibuprofen due to shared TRPA-1receptor affinity.  However Bennett and 
Hayes report that the perceptual qualities of olive oil are shared between ibuprofen and 
capsaicin, suggesting that although oleocanthal is the primary irritant in VOO, it is not the 
only one (Bennett and Hayes 2012).  This may be a result of vanilloids contained in olive 
oil activating TRPV1 receptors.  This highlights one of the many difficulties in correlating 
sensitivity to sole compounds with sensitivity to those same compounds within a food 
matrix and then making an association with dietary intake.  While there are many studies 
that report a relationship between bitter taste sensitivity and dietary intake (Palmer, Reeds 
et al. 1983, Drewnowski, Henderson et al. 1999, Kaminski, Henderson et al. 2000, Sandell 
and Breslin 2006), other studies have found no such association (Anliker, Bartoshuk et al. 
1991, Drewnowski, Henderson et al. 2007).  Although biological influences, i.e the genetic 
distribution of bitter taste receptors, may exert some influence on dietary habits, it is 
unlikely that sensitivity to PROP exerts as much influence on food choice as previously 
suggested (Bartoshuk 2000, Tepper, White et al. 2009, Catanzaro, Chesbro et al. 2013). 
 
3.9.2 Sensitivity to oleocanthal and dietary intake 
We did not find an association in this study between sensitivity to oleocanthal and dietary 
intake, as reported in a 4-day food diary.  To reiterate, oral sensitivity to oleocanthal in 
VOO is subject to large individual variation and is believed to be primarily dependent on 
differences in genetically determined levels of the TRPA1 receptor.  As the perceived 
intensity of irritation of PROP has been previously shown to influence dietary intake, we 
may expect to see associations between another irritant in food and dietary intake, however 
we did not find an association in this study.  Due to the fact that oleocanthal concentrations 
can vary across oil cultivars (Cicerale, Lucas et al. 2012),  and that individuals will perceive 
the irritation produced by oleocanthal at different intensities, establishing a link between 
sensitivity to oleocanthal and dietary intake may be difficult.    
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3.9.3 Limitations 
Throughout this study we used VOO containing oleocanthal rather than oleocanthal in 
solution and must consider the limitations of reporting perceptual attributes of a single 
compound when contained in a food matrix (Bennett and Hayes 2012).  A further limitation 
of this study was the use of a single measure of oleocanthal in VOO.  More detailed 
phenotyping could have been obtained with the incorporation of multiple concentrations of 
oleocanthal.  Also many factors other than taste sensitivity may be prominent in food 
choice.  In the age group participating in this study there are many factors that exert an 
influence over dietary habits, including finances, convenience and peer influence (Driskell, 
Kim et al. 2005).  Furthermore self-reported dietary intake does not necessarily reflect 
habitual dietary habits; however food records are an accepted method for the assessment of 
dietary intake (Gibson 2005).  The four day food diary only provides a snap shot of normal 
dietary intake and therefore is considered a limitation.  Furthermore it is possible that the 
sample size was not adequate to gain meaningful insight into a relationship between taste 
sensitivity and dietary intake.  
             
3.10 Conclusion 
In summary we report large variability in the perceived intensity of irritation produced by 
oleocanthal in a substantial screening of 168 participants in the first section of this study.  
We then substantiate that in a second screening.  Our findings support previous work and 
add to the literature investigating the mechanisms by which individuals perceive the 
pungency and irritation experienced with VOO ingestion.  We have also successfully 
identified those extremely sensitive and extremely insensitive to this distinct oropharyngeal 
irritation to participate in future research into the pharmacological activities of oleocanthal.  
 
This study is the first to focus on possible associations between sensitivity to an irritant 
compound and a bitter compound and also to investigate an association between sensitivity 
to the irritant compound oleocanthal and dietary intake.  The present data suggest that there 
is no association between individual perceived intensity of irritation from oleocanthal, and 
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dietary intake. This may be indicative of the difficulty in establishing a link between a 
phenolic compound that varies in concentration across oil and normal dietary intake.  
PROP sensitivity had no association with some bitter tasting vegetables (cabbage, spinach, 
and cauliflower), however we did observe an association between PROP sensitivity and 
intake of broccoli, which has been reported previously.  To establish a clear link between 
sensitivity to bitter and irritant compounds in foods and dietary intake is difficult and the 
results of this study reflect that difficulty.  It may be that individual taste sensitivity to these 
compounds in foods does not translate into individual dietary intake, however further 
research is needed in this area to confirm this.  We corroborate previous research showing 
large variability in oleocanthal sensitivity and this was to be expected as variation in 
receptor expression across individuals has repeatedly been shown to influence PROP 
sensitivity. 
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Chapter Four 
The effects of oleocanthal on myogenesis, protein 
synthesis and degradation as well as inflammation 
in C2C12 muscle cells 
Chapter four presents the results of experimental studies investigating the effects of the 
natural NSAID oleocanthal compared to its synthetic counterpart ibuprofen in C2C12 
mouse muscle cells.  The effects that these compounds have on proliferation, 
differentiation, protein synthesis and degradation are assessed and the anti-inflammatory 
actions of oleocanthal in skeletal muscle are reported for the first time. 
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4 The effects of oleocanthal on myogenesis, protein 
synthesis and degradation as well as 
inflammation in C2C12 muscle cells 
 
4.1 Introduction 
Non-steroidal anti-inflammatory drugs (NSAIDS) are widely prescribed to treat skeletal 
muscle inflammation and pain however they are associated with deleterious side effects 
(Mosler 2014), including renal failure (Griffin, Yared et al. 2000, Ulinski, Guigonis et al. 
2004, Tsai, Hsu et al. 2014), cardiovascular events (Cannon, Curtis et al. 2006, Grosser, 
Fries et al. 2006, Olsen, Fosbøl et al. 2015) gastrointestinal damage and lower 
gastrointestinal bleeding (Silverstein, Graham et al. 1995, Laine, Connors et al. 2003).  It is 
therefore probable that the risks associated with NSAID use may outweigh the benefits, 
certainly for the proportion of the population who are overly sensitive to the 
pharmacological effects.  NSAIDs have been suggested to be beneficial for the short term 
recovery of muscle after injury (Lanier 2003), many studies report that NSAIDs may be 
detrimental to skeletal muscle regeneration and growth processes after short term intake 
(Trappe, White et al. 2002, Bondesen, Mills et al. 2004, McCarthy, Whitney et al. 2004, 
Soltow, Betters et al. 2006, Rieu, Magne et al. 2009, Mikkelsen, Schjerling et al. 2011).  
 
Mammalian skeletal muscle is a highly dynamic and adaptive tissue, and alters in response 
to many factors such as inflammation and metabolic processes, exercise or sedentary 
behaviours (Schiaffino, Dyar et al. 2013).  Skeletal muscle health is regulated by processes 
that influence muscle fibre regeneration and also muscle mass.  Optimal skeletal muscle 
regeneration is influenced by the coordinated control of myoblast proliferation and 
differentiation in response to injury (Buckingham, Bajard et al. 2003, Bentzinger, Wang et 
al. 2012).  Satellite cells are myogenic precursor cells that give rise to myoblasts.  Satellite 
cells remain quiescent in post natal skeletal muscle until injury occurs and then they 
activate to initiate repair and regeneration (Relaix and Zammit 2012).  After injury satellite 
cells enter the cell cycle and the resulting myoblasts are stimulated to grow and proliferate 
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by several cell cycle regulatory factors (Kablar, Krastel et al. 2003).  Myogenic regulatory 
factors (MRFs) are basic helix-loop- helix (bHLH) E-box binding proteins (Sabourin and 
Rudnicki 2000).  Two MRFs of importance are MyoD which plays a role in the control 
myoblast proliferation and specification, and Myogenin which is integral in terminal 
differentiation (Sabourin and Rudnicki 2000, Charge and Rudnicki 2004).  The use of 
NSAIDs and their effects on skeletal muscle regeneration have been explored previously 
with reports that NSAID use may have detrimental effects on satellite cell proliferation  
(Trappe, Fluckey et al. 2001, Bondesen, Mills et al. 2004, Mackey, Kjaer et al. 2007, 
Mikkelsen, Schjerling et al. 2011, Fanzani, Conraads et al. 2012).   
 
Maintaining muscle mass is important for health and involves a fine balance between 
protein synthesis and protein degradation.  Protein synthesis and degradation involves a 
complex coordination of several molecular pathways, one being the Akt (Acute 
transforming retrovirus thyoma) signaling pathway.  Downstream of Akt is glycogen 
synthase kinase (GSK) 3β.  Deactivation of GSK-3 β activates the translation initiation 
factor eukaryotic initiation factor (EIF) 2B which is essential for translation initiation (Stitt, 
Drujan et al. 2004).  Furthermore Akt phosphorylates mTOR which then activates p70s6k 
and inactivates PHAS-1/ eukaryotic initiation factor 4E binding protein (4E-BP).  When 
activated p70s6k phosphorylates protein RS6 resulting in the translation of ribosomal 
proteins and elongation factors and therefore an increase in protein synthesis (Pap and 
Cooper 2002).  What is important is that the Akt/mTOR pathway is crucial in the regulation 
of protein synthesis in C2C12 myotubes and rodent models in vivo (Bodine, Stitt et al. 
2001, Pallafacchina, Calabria et al. 2002, Latres, Amini et al. 2005, Russell 2010).  In 
addition to influencing protein synthesis, Akt can reduce protein degradation through 
inhibition of the forkhead (FoxO) transcription proteins (Sandri, Barberi et al. 2013).  FoxO 
proteins upregulate atrogin-1 and MuRF-1 genes which are involved in protein breakdown 
(Bodine, Stitt et al. 2001). 
 
There are studies suggesting that NSAID use blunts protein synthesis after exercise 
(Trappe, White et al. 2002, Peterson, Trappe et al. 2003), however it seems that NSAIDs 
have no effect, or actually increase protein synthesis in  age related sarcopenia and cancer 
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cachexia in human and rodent models of disease (Strelkov, Fields et al. 1989, Smith and 
Tisdale 1993, McCarthy, Whitney et al. 2004, Rieu, Magne et al. 2009, Mikkelsen, 
Schjerling et al. 2011, Trappe, Carroll et al. 2011). 
 
Inflammatory processes also play an pivotal role in modulating responses that initiate the 
repair and maintenance of muscle (Schiaffino, Dyar et al. 2013).  Chronic inflammation has 
been associated with the pathophysiology of many disease states such as atherosclerosis, 
cancer, diabetes, neurodegenerative diseases, and chronic joint disease and also muscle 
wasting accompanying sarcopenia and cachexia (McGeer 2004, Packard and Libby 2008, 
Karlson, Chibnik et al. 2009, Grivennikov, Greten et al. 2010, Beyer, Mets et al. 2012, 
Fearon, Glass et al. 2012).  Both oleocanthal and ibuprofen attenuate inflammation and the 
anti-inflammatory actions of ibuprofen have been previously explored in skeletal muscle.  
In chapter 3 the sensory characteristics of oleocanthal have been described, but of interest is 
the pharmacological properties of this unique phenolic compound in skeletal muscle.  
 
The aim of this study is to assess and compare the effects of oleocanthal and ibuprofen on 
proliferation, differentiation, and protein synthesis and protein degradation in C2C12 
myoblasts.  A second aim to measure the effects that oleocanthal exerts on 
Lipopolysaccharide (LPS) induced inflammation in C2C12 myoblasts in comparison to 
ibuprofen.     
4.2 Methodology  
The following methods section includes methods for study 2 and study 3 with any 
variations added to the relevant chapter. 
4.2.1 C2C12 mytotubes 
C2C12 myoblasts (American type culture collection; ATCC, Manassas, VA) were grown in 
high glucose Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% foetal 
bovine serum (FBS) and 1% penicillin streptomycin (PS) (Invitrogen, Mulgrave, Vic).  As 
cells reached confluence (~90% confluent) media was changed to differentiation medium 
(DEM) supplemented with 2% horse serum.  Differentiation media was changed every 48 
hours for 6 days until myotubes reached maturity. 
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4.2.2 Cytotoxicity  
Myoblasts were plated for 24 hours and then treated with oleocanthal dissolved in 60% 
(v/v) DMSO (0.1, 0.5, 1.5, 10μM) and DMSO (0.24%) as control vehicle, LPS (0.1, 1, 10, 
100 ng/ml).  Assessment of cell viability was assayed by a measure of lactate 
dehydrogenase (LDH) activity.  A single reagent- addition, homogeneous, fluorescent assay 
(Cyto-Tox-One Homogeneous Membrane Integrity Assay ™, Promega, Madison, USA) 
was applied to the treated myoblasts and mixed in orbital shaker and mixed at 300-500rpm 
for 30-60 seconds.  The plate was then incubated at 22° for 10 minutes and fluorescence 
was recorded with an excitation wavelength of 485nm and an emission wavelength of 
520nm using an multi-mode micro plate reader (Biotek).  The assay measures the release of 
LDH that is released from lysed cells, with digitonin (300μg/ml) was used as a positive 
control. 
 
4.2.3 Proliferation 
C2C12 myoblasts were treated with oleocanthal (10, 25μM); ibuprofen (10,25μM); and 
LPS (100 ng/ml) for 24 and 48 hrs, washed and fixed.  Following fixation, myoblasts were 
incubated with 4-6-Diamidino-2- phenylindole (DAPI) (5 ug/ml). Myoblast numbers were 
determined using Image J software (NIH, Frederick, MD).  
 
4.2.4 Differentiation  
When myoblasts were confluent, DMEM containing 2% HS with and without oleocanthal 
(10μm) and ibuprofen (10μm) was added to induce differentiation.  Images were obtained 
on day 1, 3, and 5 using an Olympus IX70 micro- scope (Olympus,Mt 
Waverly,VIC,Australia), and an attached DS-U3 microscope camera with NIS-Elements 
imaging software (Nikon Instruments Inc.,Melville, NY) to assess differentiation.  At the 
same time points RNA was extracted from the cells and RT-PCR was performed on genetic 
markers of differentiation.  The media and treatments were replenished on day 1, 3, and 5 
throughout the experiment. 
 
4.2.5 Protein synthesis and degradation assays 
Myotubes were plated for and pretreated with oleocanthal(10μM) and ibuprofen (10μM) for  
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24 hours and then treated with LPS (100ng/ml) . 
4.2.5.1 Protein Synthesis 
Protein synthesis was determined by the incorporation of 3-H-tyrosine into the myotubes.  
During the last hour of treatment, 1 μCi/ml of radio-labelled [3H]-tyrosine and 2 mM L-
tyrosine (Sigma) was be added to the myotubes.  Myotubes were then treated with excess 
cold tyrosine (200 mM) and 3-H-tyrosine (1 μCi/ml) (Sigma, St. Louis, MO) for 24 hours 
in 5% CO2 air and 37oC.  Excess cold tyrosine was added to the treatments to prevent 
reincorporation of radioactivity into the myotubes (Russell, Siren et al. 2010).  Following 
the incubation period, the myotubes were washed with cold 1X PBS then incubated in 10% 
trichloroacetic acid (TCA) (Sigma, St. Louis, MO) at 4oC for 30 minutes to lift the cell 
layer.  The myotubes were then solubilised in 0.1 M NaOH + Triton X-100 (Sigma, St. 
Louis, MO) overnight at room temperature.  A 400 μl aliquot of the medium was added to 4 
ml of Ultima Gold scintillation liquid (Perkin Elmer, Boston, MA) and radioactivity was 
measured using a Wallac 1409 DSA liquid scintillation counter (Perkin Elmer, Boston, 
MA).  Genomic DNA was extracted to ensure no changes in DNA across treatment groups 
using the Allprep DNA/RNA mini kit (Qiagen, Melbourne, Australia) as per 
manufacturer’s instructions.  DNA was quantified using the NanoDrop 2000 (NanoDrop 
products, Wilmington, DE). 
 
4.2.5.2 Protein Degradation 
Protein degradation was determined by the release of 3H-tyrosine into the medium as a 
fraction of the total 3H-tyrosine incorporated into the myotubes following 24 hours of 
treatment.  Myotubes were incubated with 3H-tyrosine (2 μC/ml) for 24 hours then washed 
in serum free DMEM.  The myotubes were incubated in 2 mM cold tyrosine for 2 hours to 
remove the influence of synthesis of the degraded proteins (Russell, Siren et al. 2010), 2 
mM cold tyrosine was then added.  Following incubation an aliquot of the medium was 
added to TCA (10% w/v final concentration) and precipitated on ice for 1 hour.  400 μl of 
the supernatant was added to 4 ml of Ultimate Gold scintillation liquid for counting on the 
Wallac 1409 DSA liquid scintillation counter.  The pellet was solubilised in 0.5 M NaOH + 
0.1% Triton X-100 overnight at room temperature and remaining myotubes  washed with 
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cold 1X PBS and solubilised in 0.5 M NaOH +0.1% Triton X-100 for 2 hours at 37oC.  The 
cells were left overnight to precipitate in 10% TCA at 4oC.  After 24 hours a 400 μl aliquot 
each from the pellet and cells was added to 4 ml of scintillation liquid for counting.  
Proteolytic rate is defined as TCA-soluble radioactivity (A), divided by the sum of TCA-
soluble radioactivity (A) plus TCA-insoluble radioactivity (B) plus myotube radioactivity 
(C), then multiplied by 100.  All radioactivity measurements are expressed as counts per 
minute (CPM). 
4.2.6 Protein and Gene expression   
4.2.6.1 RNA extraction 
Total RNA was extracted using Tri-Reagent solution (Ambion Inc, Austin, TX, USA) 
according to manufacturer’s protocol.  Nanodrop 2000 (Nanodrop products, Wilmington, 
DE) was used to determine RNA quality and concentration.  First strand cDNA was then be 
generated from 500ng total RNA using High Capacity RNA-to –CDNA kit (Applied 
Biosystems, Forster City, CA).  All PCR data was normalized to 36B4 cDNA expression to 
control for variance in efficiencies of reverse transcription using the Δct method.  Real time 
PCR was performed using a Stratagene Mx3000P QPCR System and the MxPro QPCR 
software (Stratagene, La Jolla, CA) using SYBR Green chemistry.  Primers have been 
designed using Primer 3 (www.primer3.sourceforge.net) and the sequences cross checked 
for gene specificity using a BLAST search (www.ncbi.nlm.gov/BLAST). (Table 4.1) 
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Table 4.1: Primers used for RT-PCR study 2 
Gene Sequence Concentration 
  
TNFD F5’AGTAGGGAGAATCTGTTC 
AGC 3’ 
R5’CGAGAAGTCCAGTCTGTTG 3’    
 
         300nM 
         300nM 
iNOS  F 5’GGACTACTTTACTCTGGACT 
TAG 3’ 
 R5’TGTTCTTCTTTACCCTCTGT 3’ 
         300nM 
          300nM 
IL-6 F5’GGGCCTCAAAGGAAAGAA TC 
R5’TACCAGTTGGGGAACTCT GC 
 
36B4 F5’TTGTGGGAGCAGACAAT 
GTG3’ 
R5’AGTCCTCCTTGGTGAACACG3’ 
           300nM 
 
            300nM 
 
 
4.2.7 Protein Extraction 
After treatment myotubes were washed twice with PBS and lysed in RIPA buffer 
(Millipore, North Ryde, NSW) with 1μl/ml protease inhibitor cocktail (Sigma, Castle Hill, 
NSW) and 10μl Halt Phosphatase Inhibitor Single Use Cocktail (Thermo scientific, 
Rockford, IL).  Cells were scraped and transferred to an eppendorf tube.  Lysates were 
vortexed for 30 seconds, rotated for one hour at 4°C and then centrifuged at 13000rpm for 
15 minutes at 4°C.  The supernatant containing total protein extraction was then transferred 
to a new eppendorf tube and the cell pellets discarded.   
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4.2.8 BCA protein assay 
Protein concentrations were determined using the BCA Protein Assay Kit (Pierce 
Biotechnology Rockford, IL) according to manufacturer’s instructions.  A multi-mode 
micro plate reader (Biotek) was used to determine protein concentrations in sample.  
Samples were stored at -80°C until required for western blot analysis.   
 
4.2.9 Western Blotting 
Protein samples containing 20μg protein were mixed with 4x Laemmli Buffer (40% 
Glycerol, 8% sodium dodecyl sulphate (SDS), 0.25 M Tris-HCI pH 6.8%, 1% bromophenol 
blue) with 0.25 μl of β-mercaptoethanol/μl of 4X laemmli buffer, and denatured at 95°C for 
five minutes.  Samples were loaded on a graded (8–16%) Criterion Stain Free™ Tris-HCl 
Gel and separated at a current of 200 volts using the Criterion Cell (Bio-Rad, Hercules, 
CA) with electrophoresis buffer (25 Mm Tris-base, 200 mM glycine, 0.1% SDS).  The 
proteins were then  loaded to a Immun-Blot® Low Fluorescence polyvinylidene difluoride 
(PVDF) membrane (Bio-Rad, Hercules, CA) using the Criterion Transfer cell (Bio-Rad, 
Hercules, CA), with transfer buffer (25mM Tris-Base, 192 mM glycine, 10% methanol) for 
1 hour at a current of 100 volts.  Membranes were blocked with 5% skimmed milk in Tris-
buffered saline containing 0.1% Tween-20 (TBST), with gentle rocking for 1 hour at room 
temperature.  Primary antibodies (table 4.2) diluted in 5% BSA were applied and 
membranes incubated overnight at 4°C.  Subsequently membranes were washed in TBST 
(4x 10 minute washes) and then probed with secondary antibody (Table 4.2) diluted in 50% 
blocking buffer (LI-COR Biosciences, Nebraska, USA) for one hour at room temperature 
and then washed again in TBST (4 X 10 minute washes).  The membranes were imaged 
with LI-COR Odyssey CLx infra-red imaging system (LI-COR Biosciences, Nebraska, 
USA) and density of the bands was determined using Image studio Lite Version 4 (LI-COR 
Biosciences, Nebraska, USA).  
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Table 4.2: Details of primary and secondary antibodies along with concentrations used for 
western blotting 
Protein Antibody  Company Catalogue 
number 
Concentration 
 
Primary antibodies 
Glyceraldehyde-3-
phosphate dehydrogenase 
(GAPDH)  
Monoclonal Anti-
GAPDH antibody  
Cell Signaling 
Technology 
G8795 1 in 10,000 
Mammalian target of 
rapamycin (mTOR) 
Phospho-mTOR 
(Ser2448) (D9C2) 
XP® Rabbit mAb 
Cell Signaling 
Technology 
#5536 1 in 1000 
S6 Ribosomal Protein (S6 
R) 
Phospho-S6 
Ribosomal Protein 
(Ser235/236) Antibody  
Cell Signaling 
Technology 
#2211 1 in 1000 
Translation repressor 
protein 4E-BP1  
Phospho-4E-BP1 
(Thr37/46) Antibody 
Cell Signaling 
Technology 
#9459 1 in 1000 
 
Secondary antibodies 
- Anti-rabbit IgG (H+L) 
(DyLight™ 800 4X 
PEG Conjugate) 
Cell Signaling 
Technology 
#5151 1 in 5000 
- Anti-mouse IgG 
(H+L) (DyLight™ 680 
Conjugate) 
Cell Signaling 
Technology 
#5470 1 in 5000 
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4.2.10 Statistics 
Statistical analysis was performed using GraphPad Prism 4.1 (GraphPad Software, San 
Diego, CA).   For measurements of proliferation One-Way ANOVA was used to determine 
the interaction between treatment concentration (0, 0.1, 0.5,1,5,10,50 and 100 μM/ml 
oleocanthal).  Holm-Sidak Multiple Comparison Test was used to determine differences 
between groups with significance set at p < 0.05.  For measurements of differentiation a 
One-Way ANOVA was used to determine the interactions of time (day 1, 3, and 5).  Holm-
Sidak Multiple Comparison Test was used to determine differences between groups with 
significance set at p < 0.05. One way ANOVA was used to determine if there is a treatment 
effect on LPS induced inflammation after pretreatment with oleocanthal and ibuprofen.   
 
4.3 Results 
4.3.1  Oleocanthal does not affect proliferation in C2C12 myoblasts 
To determine if oleocanthal has any effect on myoblast proliferation DNA synthesis was 
assayed by measuring BrdU incorporation in C2C12 myoblasts for 24hours.  In normal 
growth conditions C2C12 myoblasts incorporated more BrdU into their cellular DNA 
compared to serum depleted cells.  Oleocanthal treatment did not have any effect on BrdU 
incorporation at 24 hours (figure 4.1) (p= 0.48).  A negative control group of serum starved 
cells were included for comparison and to assess if oleocanthal treatment attenuated the 
decreased rate of growth.  Serum free treatment significantly decreased DNA synthesis (p < 
0.01) and the addition of oleocanthal to serum starved cells had no effect (p=0.99)   
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Figure 4.1: BrDU incorporation into proliferating C2C12 myoblasts following treatment with 
oleocanthal (Oleo)(10μM), DMEM containing 10% FBS (control), DMEM without serum (SF) 
and DMEM without serum (SF) with the addition of oleo (10μM).  Data is Mean±SEM, n = 6, 
**P < 0.01 compared to control. 
 
4.3.2 Oleocanthal and Ibuprofen have no effect on proliferation 
To further investigate whether treatment with oleocanathal and ibuprofen triggered an 
increase or decrease in the proliferation of C2C12 myoblasts, cell number was counted 
following DAPI staining of the nuclei. There were no significant differences in cell number 
after 24 or 48hr treatment with oleocanthal 10μM ,or 25μM or ibuprofen 10 μM , 25μM  
(Figure 4.2 and 4.3). A serum starved group was included that showed a significant 
decrease in proliferation (p< 0.01) (Figure 4.2a and b).  Figure 4.4 shows that visually there 
are no differences in cell number after treatment with oleocanthal and ibuprofen. 
 
 
 
 
 
               
C o
n t
ro
l
o l
e o
1 0
u m S F
S F
+ O
le
o
1 0
0 .0
0 .2
0 .4
0 .6
0 .8
F
lu
ro
s
c
e
n
t
u
n
it
s
(F
U
)
* *
Chapter Four–Results 
________________________________________________________________________________________________ 
 
61 
 
 
 
 
 
 
 
 
 
Figure 4.2: Quantification of the number of nuclei per visual field by DAPI staining of C2C12 
myoblasts after 12 hours.  Images from a minimum of 10 visual fields were obtained per 
group at a 10x magnification and repeated in 2 separate experiments. ** denotes P<0.01.  
Data is mean±SEM 
 
 
 
 
 
 
 
 
 
Figure 4.3: Quantification of the number of nuclei per visual field by DAPI staining of C2C12 
myoblasts after 24 hours.  Images from a minimum of 10 visual fields were obtained per 
group at a 10x magnification and repeated in 2 separate experiments. ** denotes P<0.01. 
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Figure 4.4: Phase contrast images of C2C12 myoblasts after 48 hours treatment with 
oleocanthal (10 μM) and ibuprofen (10 μM).  Slower proliferation rates were observed in 
serum depleted conditions over 24 hrs. No changes in cell number was observed treatment of 
oleocanthal  (10 μM), or ibuprofen  (10 μM) compared to control. 
 
4.3.3 MyoD and myogenenin expression after oleocanthal and ibuprofen treatment 
To confirm visual observations of differentiation over 5 days the mRNA of differentiation 
markers MyoD and myogenin were measured (figure 4.5).  Oleocanthal and ibuprofen had 
no significant effect on expression of either myogenic gene and no difference in rate of 
differentiation was observed (figure 4.6). 
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Figure 4.5: mRNA levels of myogenic differentiation markers following treatment with 
oleocanthal (10μM) and ibuprofen (10μM) in differentiating C2C12 myoblasts. (A) Myogenin 
and (B) MyoD mRNA levels at day 1, 3 and 5 of C2C12 myoblast differentiation. N=6. Data 
presented as+/- SEM  
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Figure 4.6: C2C12 myoblast differentiation over 5 days after treatment with oleocanthal 
(10μM) and ibuprofen (10μM).  Images presented are a typical representation of a minimum 
of 3 images obtained at day 1, 3 and 5 for both groups at a 10x magnification. 
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4.3.4 Oleocanthal increases protein synthesis and has no effect on protein 
degradation 
To investigate the effect that oleocanthal has  on protein synthesis and protein 
degradation in comparison to ibuprofen the incorporation and release respectively of 
radioactive H3-Tyrosine from C2C12 myotubes was measured.  Oleocanthal significantly 
increased protein synthesis over 24 hours when compared to controls (p<0.05). Ibuprofen 
treatment also significantly increased protein synthesis (p<0.05) (figure 4.7).  No differences 
were observed in any treatment group for protein degradation (oleocanthal p=0.89), 
(ibuprofen, p=0.89) (figure 4.8).  Dexamethasone (DEX) treatment significantly 
increased  pro te in  degradat ion  by 27%  and insulin (INS) treatment significantly 
increased protein synthesis by 60%.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: Protein synthesis measured 24 hours after treatment with vehicle control, 
oleocanthal (Oleo) (10μM) ibuprofen (Ibu) (10μM), and insulin (INS) (100nM).  Oleocanthal 
and ibuprofen significantly increased protein synthesis. N= 6 per group across 2 experiments.  
* P<0.05, significantly different from control. Data presented as+/- SEM 
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Figure 4.8 Protein degradation measured 24 hours after treatment with vehicle control, 
oleocanthal (Oleo)(10μM) ibuprofen (Ibu) (10μM), and dexamethosine (Dex) (100 μM).  
Oleocanthal and ibuprofen have no effect on protein degradation compared to control.  N= 6 
per group across 2 experiments. * P<0.05, significantly different from control. Data presented 
as+/- SEM 
 
4.3.5 The effects of oleocanthal on phosphorylation of proteins involved in protein 
synthesis 
Due to the loss of protein samples the Western Blot analysis could not be repeated. 
Visually it would seem that oleocanthal and ibuprofen alone, oleocanthal with LPS 
treatment, or pretreatment with oleocanthal and ibuprofen have no effect on mTOR, 4EBP, 
or RS6 phosphorylation (figure 4.9). 
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Figure 4.9 Effect of oleocanthal (oleo) (n=2), ibuprofen (ibu) (n=2), LPS (n=2), LPS with 
oleocanthal (LPS+Oleo) (n=2) pretreatment with oleocanthal (Pretreat Oleo)(n=2), 
Pretreatment with ibuprofen (Pretreat Ibu)(n=1) and control (n=2) on phosphorylation of 
mTOR, 4EPP-1, and RS6  
 
1.1.6 Oleocanthal and ibuprofen attenuate LPS induced inflammation 
As reported previously acute LPS challenge in C2C12 myotubes promotes the release of 
inflammatory mediators (Verhees, Pansters et al. 2013).  This is observed with significant 
increases in mRNA expression of pro inflammatory mediators IL-6 (p<0.01), TNF α 
(p<0.01), and iNOS (p<0.01) after treatment with LPS for 2 hours.  Pretreatment with 
oleocanthal and ibuprofen for 24hours significantly attenuated the LPS induced expression 
of IL-6 (p<0.01) (figure 4.10a), iNOS (p<0.01), (figure 4.10b) and TNF α (p<0.01), (figure 
4.10c) 
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Figure 4.10 Effects of pretreatment: with oleocanthal and ibuprofen (10μM ) for 24 h on LPS 
induced inflammatory markers.  C2C12 myotubes were treated with oleocanthal and 
ibuprofen for 24 h and then LPS (100ng) for 2 h.  Gene expression of IL-6 (a) iNOS (b) and 
TNF α (c) were measured.   Data are expressed as means ± SEM  *P< 0.05,**P < 0.01 
pretreatment with oleocanthal or ibuprofen VS LPS . ##P <0.01 treatment groups compared 
with control 
 
4.4 Discussion 
Oleocanthal and ibuprofen had no significant effect on C2C12 myoblast proliferation.  
While some authors have reported no effect of NSAIDs on satellite cell proliferation 
(Thorsson, Rantanen et al. 1998, Paulsen, Egner et al. 2010), numerous studies have 
suggested that synthetic NSAIDs such as ibuprofen reduce satellite cell proliferation 
(Trappe, Fluckey et al. 2001, Bondesen, Mills et al. 2004, Shen, Li et al. 2005, Mackey, 
Kjaer et al. 2007, Mikkelsen, Schjerling et al. 2011, Fanzani, Conraads et al. 2012, 
a b 
c 
*
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Markworth and Cameron-Smith 2013).  For example Shen and collegues show that a COX 
2 inhibitor decreased proliferation and inhibited maturation of myogenic precursor cells 
(Shen, Li et al. 2005), and an early study demonstrated the NSAID Indomethacin inhibits 
myoblast proliferation in human fetal cells (Zalin 1987).   
These deleterious effects may be related to the inhibition of COX enzymes and downstream 
prostaglandins that are required for satellite cell activity (Mackey, Kjaer et al. 2007).  
Prostaglandins are important for myoblast proliferation and muscle growth and are 
synthesized in regenerating muscle (Palmer, Reeds et al. 1983, McArdle, Edwards et al. 
1994, Trappe, Fluckey et al. 2001).  However it has been suggested that the NSAID 
Indomethacin may inhibit satellite cell activation via other pathways independent of  COX 
(Bamman 2007, Mackey, Kjaer et al. 2007).  Both oleocanthal and ibuprofen are known to 
attenuate the activity of COX 1 and 2 enzymes, however in the present study neither 
oleocanthal, a natural NSAID, nor ibuprofen, a synthetic NSAID, affected proliferation.  
 MyoD is required for skeletal muscle cell determination and early myoblast differentiation, 
and is expressed in proliferating cells before differentiation.  Proliferating myoblasts 
withdraw from the cell cycle to become differentiated myocytes that express Myogenin, 
(Sabourin and Rudnicki 2000, Zammit, Golding et al. 2004).  The  myogenic differentiation 
of satellite cells and fusion with existing muscle fibres is crucial in the process of 
regeneration (Seale, Sabourin et al. 2000).  Oleocanthal and ibuprofen treatment had no 
effect on either myogenin or MyoD mRNA expression measured at day 1, 3, and 5 of 
differentiation and this corresponded with no observed effects on myotube formation.  A 
possible reason for this may be due to the fact mRNA expression of these markers was 
compared to the control on day 1.  A comparison to the mRNA expression of an untreated 
sample at day 0 before treatment commenced, may result in increased expression of 
Myogenin and myoD on days 1-5 compared to day 0 for both the control and NSAID 
groups.  
Maintaining muscle size is an important component of skeletal muscle health and the 
balance between protein synthesis and degradation is crucial.  In the present study both 
oleocanthal and ibuprofen significantly increase protein synthesis in C2C12 myotubes, 
without effecting protein degradation.  This is in contrast to several reports stating that 
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NSAIDs may decrease protein synthesis after intense resistance exercise in humans 
(Trappe, Fluckey et al. 2001, Trappe, White et al. 2002) and decrease muscle hypertrophy 
in humans and mice (Soltow, Betters et al. 2006, Novak, Billich et al. 2009).  While there is 
much evidence alluding to NSAID administration and a connection with adverse effects on 
muscle regeneration and growth after mechanical loading, studies investigating the role of 
NSAIDS on cancer cachexia and sarcopenia, suggest muscle mass is preserved when 
NSAIDs are administered  in animal and human studies (McCarthy, Whitney et al. 2004, 
Sartorelli and Fulco 2004, Beyer, Mets et al. 2012, Schiaffino, Dyar et al. 2013).   
The mechanism by which oleocanthal increases protein synthesis in this study is not 
confirmed.  mTOR is a crucial regulator of protein synthesis, and RS6, or 4E-BP1 are 
proteins down stream of mTOR that are important in protein translation initiation.  We 
could not determine if oleocanthal and ibuprofen influenced the phosphorylation of mTOR, 
RS6, or 4E-BP1 due to lack of samples and therefore statistical power, however these 
preliminary blots have been included for observation.   
Pretreatment with oleocanthal and ibuprofen significantly attenuated LPS induced TNF α 
expression in the present study.  Early stages of muscle regeneration are characterized by 
increased expression of TNFα, however several studies have demonstrated that TNF α may 
also have an inhibitory effect on skeletal muscle cell differentiation and protein synthesis in 
vitro and in vivo (Greiwe, Cheng et al. 2001, Langen, Van Der Velden et al. 2004, Moresi, 
Pristera et al. 2008).  Oleocanthal decreases levels of TNF α in J774 macrophages (Scotece, 
Gómez et al. 2012) and the present study suggests that oleocanthal and ibuprofen exhibit 
similar attenuation of TNFα in C2C12 myotubes. 
In humans an increase in IL-6 decreases circulating IGF1, the latter is a muscle growth 
factor (Lazarus, Moldawer et al. 1993, Haddad, Zaldivar et al. 2005).  Chronic exposure 
and high levels of IL-6 decrease skeletal muscle mass (Stenholm, Maggio et al. 2010) and 
increase protein degradation in C2C12 myotubes (Ebisui, Tsujinaka et al. 1995).  The 
present study shows that both ibuprofen and oleocanthal attenuate acute LPS induced IL-6 
expression in C2C12 myotubes after pretreatment for 24 hours.  A recent study highlighting 
the efficacy of the anti-inflammatory action of oleocanthal demonstrated that this 
compound attenuates IL-6 in both ATDC5 chondrocytes and J774 macrophages (Scotece, 
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Gómez et al. 2012).  The findings from the present study are the first to demonstrate the 
anti-inflammatory actions of oleocanthal against LPS challenge and the resultant 
attenuation of IL-6 gene expression in muscle.  
Oleocanthal has attenuated LPS induced iNOS expression in human chondrocytes 
highlighting this natural NSAID as a potential therapeutic option for the treatment of joint 
degenerative diseases (Iacono, Gómez et al. 2010).  Frost and collegues report that the 
expression of iNOS in mouse muscle cells inhibits the mTOR pathway and subsequent 
decreased phosphorylation of the downstream targets 4E-BP1 and RS6 (Frost, Nystrom et 
al. 2009).  It is possible that inhibiting iNOS production in skeletal muscle may be a 
potential target in the therapeutic treatment of muscle wasting (Hall, Ma et al. 2011).    
There are several limitations to be considered in this study.  C2C12 cells have been widely 
used for demonstrating the effects that both natural and synthetic compounds exert on 
muscle regeneration, growth and inflammation, however they do not fully represent in vivo 
physiology.  Results from in vitro studies are difficult to translate to in vivo due to different 
biological factor such as differing levels of inflammation.  Furthermore synthesized 
oleocanthal was used in vitro model of sepsis (Frost, Nystrom et al. 2009).  It is yet to be 
determined whether these results can be extrapolated to in vivo conditions where 
oleocanthal is contained in a food matrix.  Also, to determine if oleocanthal and ibuprofen 
work independently of mTOR/Akt pathways these experiments need to be repeated with 
adequate sample number. 
In conclusion oleocanthal and ibuprofen had no influence on proliferation or markers of 
differentiation in C2C12 myotubes.  Both oleocanthal and ibuprofen increased protein 
synthesis with no effect on protein degradation.  Further studies are needed to determine the 
mechanisms by which this occurs.  Finally oleocanthal and ibuprofen attenuate LPS 
induced inflammatory markers, which are linked to skeletal muscle regeneration and 
growth.  This study confirms the anti-inflammatory effects of oleocanthal and for the first 
time explores these properties in skeletal muscle.  Oleocanthal exerts similar effects to 
ibuprofen in vitro supporting the possibility that it may act as an anti-inflammatory agent in 
muscle. 
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Chapter Five 
Investigating individual differences in perceptual 
sensitivity to oleocanthal linked to differential 
effects from oleocanthal treatment in muscle 
 
Chapter five presents the results of experimental studies investigating differential effects of 
the two NSAIDs oleocanthal and ibuprofen in primary human muscle cells obtained from 
biopsies of the hypersensitive and hyposensitive subjects screened in study 1.   
The study explores differences in mRNA expression of TRPA-1 and other inflammatory 
markers in response to endotoxin challenge in both sensitivity groups, differences in protein 
synthesis and degradation and investigates the anti-inflammatory effects of oleocanthal in 
human skeletal muscle cells. 
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5 Investigating individual differences in perceptual 
sensitivity to oleocanthal linked to differential 
effects from oleocanthal treatment in muscle 
 
5.1 Abstract 
Oleocanthal, a VOO phenolic compound exerts anti-inflammatory actions in mouse muscle 
cells similar to the NSAID ibuprofen.  These compounds target the transient receptor 
potential ankyrin 1 (TRPA-1) receptor in the oropharynx, which explains the variability and 
specificity of the throat irritation accompanying VOO ingestion.  There is a suggested link 
between the sensory; the way we perceive chemicals in foods, and the systemic; the way 
those chemicals incite molecular responses and exert pharmacological actions.  The aims of 
this study were firstly to determine if TRPA-1 mRNA expression differed in muscle cell 
lines developed from subjects classified as hypo and hypersensitive to the perceptual 
characteristics of oleocanthal and if treatment with oleocanthal regulated TRPA-1 mRNA.   
A second aim was to then determine if oleocanthal and ibuprofen differentially influence 
protein synthesis, protein degradation and inflammatory responses to endotoxin LPS in 
muscle cell lines derived from those extremely sensitive (hypersensitive) and those 
extremely insensitive (hyposensitive).  No differences in TRPA-1 were observed in muscle 
cell lines from hypersensitive versus hyposensitive subjects without treatment or following 
treatment with oleocanthal or ibuprofen.  However LPS challenge increased TRPA-1 
mRNA levels in muscle cells derived from hyposensitive compared to hypersensitive 
subjects.  Treatment with oleocanthal and ibuprofen significantly increases protein 
synthesis in muscle cells from hyposensitive subjects.  There was no effect on protein 
degradation.  While the interaction between sensitivity status on pre-treatment with either 
induced inflammatory cytokines could not be verified, an attenuation of inflammation in 
pooled human myotubes by oleocanthal is reported for the first time.   
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5.2 Introduction  
There is considerable variation in the way that individuals perceive the irritation in the 
orophanx accompanying VOO ingestion (Beauchamp, Keast et al. 2005, Cicerale, Breslin 
et al. 2009, Bennett and Hayes 2012).  Oleocanthal is the phenolic responsible for this 
unique sensory characteristic and the irritation produced is identical in sensory attributes to 
that of the NSAID ibuprofen, despite both compounds being structurally dissimilar.  The 
sensory similarities between oleocanthal and ibuprofen and the subsequent findings that 
both compounds target the same inflammatory pathway has led to numerous in vitro studies 
aimed at elucidating the extent of oleocanthal’s pharmacological properties.  
  
Oleocanthal attenuates inflammatory markers in several models of disease, including 
Alzhemers disease, arthritis, and cancer (Scotece, Gómez et al. 2012).  Oleocanthal and 
ibuprofen target the transient receptor potential ankyrin 1 (TRPA-1) receptor that is 
expressed in nociceptive neurons and is involved in inflammatory pain (Hu, Tian et al. 
2010).  TRPA1 agonists are important not only in gustative sensations but also in the 
generation of pain and neurogenic inflammation and skin sensitisation (Xu, Delling et al. 
2006, Trevisani, Siemens et al. 2007). TRPA-1, also known as p120 was first identified in 
human fibroblasts, albeit at very low levels (Jaquemar, Schenker et al. 1999).  TRPA-1 is 
activated by both environmental irritants and also pungent chemicals such as gingerol 
(ginger), garlic (allicin) and α,β-unsaturated aldehydes such as iodoacetamide and curcumin  
(Jordt, Bautista et al. 2004, Bautista, Movahed et al. 2005, Karashima, Damann et al. 2007, 
Avonto, Taglialatela-Scafati et al. 2011) and more recently by oleocanthal contained in 
VOO (Peyrot des Gachons, Uchida et al. 2011).  Natural TRPA-1 agonists are desirable not 
only in sensory science applications but also may have application in pharmacology 
(Bassoli, Borgonovo et al. 2013).  A select group of NSAIDs, other than ibuprofen, act as 
agonists of TRPA-1 by direct interaction with the TRPA-1 channel (Hu, Tian et al. 2010).  
Oleocanthal and ibuprofen specifically target TRPA-1 receptors that are spatially located in 
the oropharyngeal region (Peyrot des Gachons, Uchida et al. 2011).  This suggests that the 
genetic distribution of receptor levels may explain the variance in individual sensory 
perception of both compounds.  
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 An interesting point raised with the discovery of specificity of oleocanthal and ibuprofen 
to TRPA-1 receptors in the oropharynx, is contained in the formulated hypothesis of 
Fischer in the 1960’s.  Fischer suggested that the sensory responses to a chemical can 
indicate the pharmacological efficiency of that chemical in the body (Fischer, Griffin et al. 
1965).  This has also been recently alluded to with the hypothesis from Clarke and 
collegues that expression of  the bitter taste receptors TR2 will mediate the physiological 
effects of bitter tasting drugs (Clark, Liggett et al. 2012).  For example an individual with 
low expression of TR2 genes may have reduced physiological response to particular 
compounds.  Therefore those who are highly sensitive or insensitive to the oropharangeal 
irritation of oleocanthal may also have different systemic responses to the anti-
inflammatory actions of this natural NSAID.   
 
The aim of this study is to measure TRPA-1 mRNA levels in human primary muscle 
cultures grown from biopsy samples taken from subjects classified as hyper and 
hyposensitive to the throat irritation of oleocanthal in chapter 3.  A second aim is to 
investigate the effect of oleocanthal and ibuprofen on protein synthesis and protein 
degradation in cultured skeletal muscle cells from subjects classified as hyper or 
hyposensitive.  The final aim is to determine if is there is a link between the sensory 
responses to oleocanthal and the anti-inflammatory actions of this compound in these same 
cultured cells. 
5.3 Methodology  
Please see methods chapter 4 for protein synthesis and protein degradation methodology 
(4.5.1. 4.5.2) and for protein and gene methodology (4.6.1, 4.6.2, 4.6.3, and 4.6.4).  
 
5.3.1 Harvest and preparation of human primary myotubes 
A muscle biopsy sample (~150 mg) taken from the vastus lateralis in 3 healthy sensitive 
phenotypes (1 male and 2 females), and 3 healthy insensitive phenotypes (1 male, 2 
females), was used to prepare a primary human muscle culture as published by our group 
previously, but with minor modifications (Wallace, Hock et al. 2011).  In brief, the excised 
muscle was immersed, extensively washed then minced in ice-cold Hams F-10 medium.  
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The minced tissue was then digested in 25 ml of 0.05% Trypsin/EDTA at 37°C with 
agitation for 20 min to release the myoblasts.  The supernatant containing the myoblasts 
was then collected.  This process was repeated a further two times to breakdown any 
remaining tissue, followed by the addition of 10% HS.  Connective tissue was removed by 
filtering the supernatant through a pre-wet 74 μm (15 mm diameter) filter followed by 
centrifugation for 10 min at 1600 rpm.  The cell pellet was re-suspended in Hams F-10 
medium containing 20% FBS, 25 ng/ml bFGF, 0.05% pen/strep and 0.05% amphoterecin 
(human growth media).  The cells were then seeded on to an uncoated 25 cm2 flask and 
incubated at 37°C for 30 min to induce fibroblast attachment, leaving myoblasts suspended 
in the medium.  The medium was collected and this process was repeated for another 30 
min.  The medium was then collected and seeded on to 25 cm2 flask coated with an 
extracellular matrix (ECM).  The resulting primary cell lines from 5 participants were 
maintained in the human growth media in humidified air at 37°C and 5% CO2 and then 
frozen in cryotubes in liquid nitrogren until used.   
5.3.2 Primary myotubes 
Myoblasts were seeded onto extra cellular matrix coated 75cm2 flasks and grown in HAMS 
F10 medium with 20% FBS, 1% PS and 2.5μl amphotericin B.  At ~ 80% confluence 
differentiation was induced by the Hams F-12 medium with 2% HS for 7-10 days.  
Differentiation media was changed every 48 hours for 6 days until myotubes reached 
maturity. 
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Table 5.1: Primers used 1for RT-PCR study 3 
Gene Sequence Concentration 
TNFD F 5’ AGT AGG GAG AAT CTG TTC AGC 3’ 
R 5’ CGA GAA GTC CAG TCT GTT G 3’         
300nM   
300nM 
IL-6  F 5’ GG ACT ACT TTA CTC TGG ACT 
TAG 3’ 
 R 5’ TG TTC TTC TTT ACC CTC TGT 3’ 
150Nm 
    
200nM 
MCP-1 F 5’ CGC CTC CAG CAT GAA AGT CT 3’ 
R 5’GGA ATC AAG GTG GCT GCT ATC 3’ 
300Nm 
300nM 
IL-8 F 5’GCT CTA CCC TGC CCC CTT T 3’ 
R 5’TTC CAG GGA TTC TGG TTC ACA 3’ 
300nM 
300nM 
RPLPO F 5’TTG TGG GAG CAG ACA ATG TG3’ 
R 5’ AGT CCT CCT TGG TGA ACA CG3’ 
300nM 
300nM 
 
 
5.4 Results 
5.4.1 Primary Muscle Cells 
From study 1 (chapter 3), 3 hyposensitive and 3 hypersensitive individuals (males n=2, 
females n=4 32±17 years) were identified and agreed to undergo a muscle biopsy.  From 
these biopsies primary muscle cell lines were grown.  One cell line from a hypersensitive 
individual was lost to bacterial infection. 
5.4.2 Differences in TRPA-1 mRNA expression from muscle cell lines from subjects 
classified as hyper or hyposensitive to oleocanthal 
 
 TRPA-1 expression was very low in the human primary myotubes (mean±SEM CT value 
29.4±0.2)  No significant differences in TRPA-1 mRNA was observed between hyper and 
hyposensitive samples before or after oleocanthal (p=0.87) or ibuprofen treatment (p=0.84).  
LPS treatment significantly increased TRPA-1 expression in primary muscle culture from 
hyposensitive (p<0.01) compared to hypersensitive (Figure 5.1) subjects and significantly 
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increased TRPA-1 mRNA expression compared to controls.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: TRPA-1 expression in primary human myotubes derived from hyposensitive (n=3) 
and hypersensitive (n=2) subjects.  Treatment with LPS significantly increased expression of 
TRPA-1 in hyposensitive individuals in comparison to hypersensitive **p<0.01. LPS 
treatment significantly increased TRPA-1 expression compared to control in both hypo and 
hyper sensitive subjects (##p<0.01). Data expressed as mean ±SEM 
 
5.4.3 Oleocanthal increases protein synthesis in subjects hyposensitive to oleocanthal 
 
To investigate any differential effect that oleocanthal has on protein synthesis and protein 
degradation in cell cultures derived from hyper and hypo sensitive individuals the 
incorporation and release respectively, of radioactive H3-Tyrosine was measured.  
Oleocanthal significantly increased protein synthesis over 24 hours in hyposensitive subject 
1 (p=<0.01) subject 2 (p=<0.05), and subject 3 (p<0.05) by approximately 160%, 40% and 
80% respectively. Ibuprofen treatment also significantly increased protein synthesis in 
hyposensitive subject 1 (p<0.01) subject 2 (p<0.05), and subject 3 (p<0.05) (figure 5.2) by 
approximately 140%, 50% and 69% respectively.  Oleocanthal did not increase protein 
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synthesis in hypersensitive subject 1 (p= 0.55) or subject 2 (p= 0.99).  Similarly ibuprofen 
did not increase protein synthesis in hypersensitive subject 1 (p= 0.28) or subject 2 (p= 
0.82).  When protein synthesis data was pooled both oleocanthal and ibuprofen treatments 
significantly increased protein synthesis in subjects classified as hyposensitive by 
approximately 85% (Figure 5.3).  There was no significant increase in protein synthesis in 
those classified as hypersensitive with oleocanthal treatment (p= 0.92) or ibuprofen 
treatment (p= 0.43).    
An insulin treatment group was used as a positive control as insulin significantly increases 
protein synthesis in muscle cells (Wright, Brown et al. 2015).  Insulin (INS) treatment 
significantly increased protein synthesis in all cell lines tested, as was independent of 
sensitivity status, by 107%.  Genomic DNA was measured to ensure cell number did not 
change with any treatment.  There were no significant differences in DNA between either 
treatment or control groups  
 
5.4.4 Oleocanthal has no effect on protein degradation in hypo or hypersensitive 
subjects 
 
No differences were observed for oleocanthal treatment on protein degradation in 
hyposensitive subject 1 (p= 0.99), subject 2 (p=0.55), and subject 3 (p= 0.94), 
hypersensitive; subject 1 (p= 0.90) or subject 2 (p= 0.79).  Similarly ibuprofen had no 
effect on hyposensitive subject 1 (p= 0.98.), subject 2 (p= 0.98), and subject 3 (p= 0.94), 
however it did increase protein degradation in hypersensitive subject 1 p< 0.01, but not 
subject 2 (p= 0.74) (figure 5.4).  Dexamethasone (DEX) treatment was used as a negative 
control as it significantly increases protein degradation in muscle cells (Yang, Wei et al. 
2007).  DEX treatment significantly increased protein degradation by 80%.  When data was 
pooled from both hyposensitive and hypersensitive cell lines there were no significant 
differences for protein degradation from either treatment (figure 5.5).   
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Figure 5.2: Protein synthesis measured 24 hours after treatment with vehicle control, oleocanthal (Oleo) (10μM) ibuprofen (Ibu)(10μM), 
and 100 nM insulin (INS).  Oleocanthal and ibuprofen significantly increases protein synthesis in cells from hyposensitive subjects 1, 2 and 
3 but does not increase synthesis in cells from hypersensitive subjects 1 or 2.  N= 6 per group across 2 experiments. *P<0.05, ** P<0.001, 
significantly different from control. Data expressed as mean±SEM 
*
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Figure 5.3: Pooled data from hyposensitive and hypersensitive participants. Protein synthesis 
measured 24 hours after treatment with vehicle control (control), oleocanthal (oleo)(10μM) 
ibuprofen (ibu) (10μM) Oleocanthal and ibuprofen significantly increases protein synthesis in 
cells from hyposensitive but does not increase synthesis in cells from hypersensitive subjects  
P* <0.05, ** P<0.001, significantly different from control 
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Figure 5.4: Protein degradation measured 24 hours after treatment with vehicle control, oleocanthal (Oleo) (10μM), ibuprofen (Ibu) 
(10μM), and 10 μM dexamethosine (DEX).  Oleoxcanthal and ibuprofen had no effect on protein degradation compared to control in 
hypersensitive 2 and hyposensitive 1, 2 and 3, however ibuprofen significantly increased protein degradation in hypersensitive 1. N= 6 per 
group across 2 experiments. *P=<0.05, ** P<0.001, significantly different from control. Data expressed as mean±SEM 
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Figure 5.5: Pooled data from hypo sensitive and hyper sensitive participants.  Protein 
degradation measured 24 hours after treatment with vehicle control, oleocanthal (oleo) 
(10μM), ibuprofen (ibu) (10μM).   
 
5.4.5 Oleocanthal and ibuprofen do not differentially attenuate LPS induced 
inflammation in cells from hyposensitive versus hypersensitive 
There were significant increases in mRNA levels of pro inflammatory mediators IL-6, 
TNF α, IL-8 and MCP-1 after treatment with LPS for 2 hours. It could not statistically 
be determined if there was a treatment effect of pretreatment with oleocanthal and 
ibuprofen due to too much variability in the data across experiments and cell lines.   
IL-8 expression was greater in those hypersensitive compared to hyposensitive after 
LPS treatment (p<0.01), (figure 5.6).  However this was not observed with TNFα 
(p=0.84) or IL-6 (p=0.29).  
5.4.6 Oleocanthal and ibuprofen attenuate LPS induced inflammation in human 
primary cells 
When the data was pooled from 3 human primary cell lines oleocanthal and ibuprofen 
significantly attenuated IL-8, IL-6 and TNFα, however both compounds had no effect 
on MCP-1 (figure 5.7). 
H y
p o
s e
n s
it i
v e
c o
n t
ro
l
H y
p e
rs
e n
s i
t iv
e
c o
n t
ro
l
H y
p o
s e
n s
it i
v e
o l
e o
H y
p e
rs
e n
s i
t iv
e
o l
e o
H y
p o
s e
n s
it i
v e
Ib
u
H y
p e
rs
e n
s i
t iv
e
ib
u
0 .0
0 .5
1 .0
1 .5
P o o le d d e g r a d a tio n
3
H
T
y
ro
s
in
e
re
le
a
s
e
(A
U
)
 
Chapter Five- Results 
_____________________________________________________________________________________________ 
 
85 
 
                         
Figure 5.6: Differences in IL-8 mRNA expression in cells from hypo sensitive vs hyper 
sensitive individuals.  Cells were pretreated with oleocanthal (Pretreatment oleo) and 
ibuprofen ( pretreatment ibu) for 24 h and then LPS was added (100ng) for 2 h.   Data are 
expressed as mean±SEM **P < 0.01, *P<0.05 pretreatment with oleocanthal and 
ibuprofen VS LPS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7: Pooled data from 2 human cell lines. Cells were treated with oleocanthal alone 
(OLEO) (10μM), Ibuprofen alone (IBU)(10μM), pretreated with oleocanthal 
(LPS+OLEO) and pretreated with ibuprofen (LPS+IBU) for 24 h and then LPS was added 
(100ng) for 2 h.  Gene expression of IL-8 (a) IL-6, (b), MCP-1 (c) and TNF α (d) were 
measured.   Data are expressed as means ± SEM **P < 0.01, *P<0.05 pretreatment with 
oleocanthal and ibuprofen VS LPS . ##P <0.01 treatment groups compared with control 
A
B
C
D
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5.5 Discussion 
The hypothesis of this study, based on an early suggestion by Fischer (Fischer, Griffin 
et al. 1965) was that there would be different basal levels of TRPA-1 mRNA in cells 
derived from hypersensitive versus hyposensitive subjects.  Also it was expected that 
there would be differential treatment effects of oleocanthal and ibuprofen on cells 
derived from hypersensitive compared to hyposensitive individuals. 
There were no differences in baseline TRPA-1 mRNA, and no differences after 
oleocanthal and ibuprofen treatment in cell lines from the two sensitivities in this study, 
however myotubes derived from those hyposensitive had greater mRNA expression of 
TRPA-1 in response to LPS challenge.  TRPA-1 mRNA is expressed in various tissues 
but is reported to be lowly expressed in skeletal muscle in rodent studies and in human 
fibroblasts, however is greatly expressed in cells with sensory functions (Nagata, 
Duggan et al. 2005, H Jiang, Gamper et al. 2011).  Pain and neurogenic inflammation 
produced by LPS are dependent on TRPA-1 channel activation in nociceptive sensory 
neurons, and TRPA-1 channels are integral in the biological response to LPS in somatic 
and visceral nociceptor neurons (Meseguer, Alpizar et al. 2014).  This may explain the 
increased expression of TRPA-1 in response to LPS treatment in muscle cells.  Because 
TRPA-1 mRNA is not highly expressed in skeletal muscle cells any differential effects 
between oleocanthal and ibuprofen treatment without LPS may not be measurable.  
TRPA-1 protein levels were not measured in this study, which is a limitation and is of 
importance in future studies to determine TRPA-1 protein expression.  
 
In contrast to the hypothesis of this study myotubes grown from human skeletal muscle 
biopsies taken from those hyposensitive to the throat irritation had greater expression of 
TRPA-1 mRNA induced by LPS treatment.  Also protein synthesis was increased after 
oleocanthal and ibuprofen treatment in those hyposensitive to the throat irritation of 
oleocanthal in contrast to hypersensitive.  This may suggest that the potential effects 
that oleocanthal exerts via its affinity to TRPA-1 receptor levels could be tissue specific 
rather than systemic.  While it is clear that TRPA-1 plays a role in inflammation and 
pain in both neural and non- neuronal tissue (Bautista, Pellegrino et al. 2013), to date its 
functionality in human skeletal muscle has not been investigated, so therefore we can 
only speculate that it may play a role in inflammation in skeletal muscle metabolism.  
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The novel finding that oleocanthal and ibuprofen increase protein synthesis in C2C12 
myotubes was reported in chapter 4.  Of interest in the present study is the differential 
effects that oleocanthal and ibuprofen exert on protein synthesis in human muscle cell 
lines derived from hypersensitive and hyposensitive individuals.  Oleocanthal and 
ibuprofen both significantly increased protein synthesis in cell lines derived from 
individuals classified as hyposensitive to the oropharyngeal irritation in study 1 
compared to cell lines derived from  hypersensitive subjects.  This is counter to our 
hypothesis that cells derived from hypersensitive subjects would show greater increases 
in protein synthesis in line with greater sensory response to the oropharyngeal irritation. 
However increased protein synthesis in skeletal muscle cells corresponding to a 
particular sensitivity to irritation in the oropharynx from oleocanthal is important.  
However as TRPA-1 mRNA levels in human muscle cells has not been explored in 
depth, and the up regulation of factors involved in protein synthesis was not measured 
in this study, conclusions are only speculative.  Future studies are needed to gain 
understanding on why individuals who does not perceive the throat irritation evoked by 
oleocanthal, would have greater skeletal muscle protein synthesis in vitro.  In line with 
study 2 there were no significant effects of oleocanthal or ibuprofen on protein 
degradation in both sensitivity groups, with the exception of hypersensitive subject 1, 
and the reason for this is unknown.  
 
A central aim of this study was to determine if oleocanthal differentially attenuates 
inflammation in those hypersensitive to the throat irritation compared with those 
hyposensitive.  Although there are differences in mRNA expression of TRPA-1 and IL-
8 between phenotypes a treatment effect from pretreatment with oleocanthal and 
ibuprofen cannot be reported due to large variability across cell lines and across 
experiments.  In study 2 (chapter 4) the attenuation of LPS induced IL-6, TNFα, and 
iNOS mRNA levels from pretreatment with oleocanthal and ibuprofen was observed in 
C2C12 myotubes.  
 
In the present study there were significant increases in mRNA levels of pro 
inflammatory mediators IL-6, TNF α, IL-8 and MCP-1 after treatment with LPS for 2 
hours.  Pooled data obtained in this study from 2 human muscle cell lines, demonstrates 
the attenuation of LPS induced IL-6, IL-8 and TNFα mRNA expression in cells 
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pretreated with oleocanthal and ibuprofen.  However MCP-1 expression was not 
attenuated.  Although iNOS expression was measured in study 2, due to time constraints 
and issues surrounding iNOS primer optimization in human cDNA, iNOS mRNA 
expression was not investigated in this study.   
 
The biological role that IL-8 may have in the etiology of skeletal muscle regeneration 
and growth is at this stage unknown (Pedersen and Febbraio 2012).  Whilst the effects 
of IL-8 in skeletal muscle are unclear it is established that IL-8 plays a central role in 
mediating acute inflammation (He, Qu et al. 2013).  This study reports for the first time 
a significant attenuation of IL-8 mRNA upregulation in human primary myotubes with 
both a natural and synthetic NSAID, however pretreatment with oleocanthal and 
ibuprofen did not attenuate MCP-1.  NSAIDs have been reported to increase expression 
of MCP-1 in vivo after exercise, however there are no other studies investigating 
NSAID use and MCP-1 expression in muscle cells (Mikkelsen, Schjerling et al. 2011). 
  
IL-6 and TNFα exhibit adverse effects on skeletal muscle regeneration and growth 
processes (Langen, Van Der Velden et al. 2004, Toth, Matthews et al. 2005, Kandarian 
and Jackman 2006, Moresi, Pristera et al. 2008, Stenholm, Maggio et al. 2010). 
Inflammation has also been highlighted as a potential factor that contributes to the onset 
and progression of  age related skeletal muscle wasting (Vandervoort 2002, Argiles, 
Busquets et al. 2005, Haddad, Zaldivar et al. 2005, Roubenoff 2012).  Therefore natural 
therapeutic compounds targeting these inflammatory cytokines may be of interest in 
future pharmacology directed at skeletal muscle health. 
 
To conclude this study demonstrates for the first time that primary cell cultures 
developed from subjects that are hyposensitive to the throat irritation of oleocanthal 
show greater expression of TRPA-1 mRNA induced by LPS challenge compared to 
those who are hyper, or extremely sensitive to oleocanthal’s perceptual irritancy.  
Primary cell cultures developed from subjects that are hypersensitive to the throat 
irritation cells have greater expression of LPS induced IL-8 mRNA.  This novel study 
also reports that oleocanthal increases protein synthesis in cells derived from those who 
are classified as hyposensitive compared to those who are hypersensitive.  For the first 
time the anti-inflammatory actions of the natural NSAID oleocanthal and its synthetic 
counterpart ibuprofen were observed and compared in primary human muscle cells.  
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Future studies are required to gain an understanding into the molecular pathways that 
regulate these processes and to gain insight to the translation of individual perceived 
differences in the sensory attributes of oleocanthal and the actions of oleocanthal in the 
regulation of skeletal muscle growth and inflammatory processes. 
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Chapter Six 
Conclusions and Future Directions 
Chapter Six presents the conclusions drawn from the three studies presented in this thesis 
and highlights the future work that is required to fully elucidate the mechanisms by which 
oleocanthal increases protein synthesis and attenuates inflammation in muscle.   Chapter six 
also contains a study that would give insight on a possible link between TRPA-1 sensory 
receptor levels,TRPA-1 mRNA levels in skeletal muscle and the pharmacological actions 
of oleocanthal.  Finally Chapter 6 summarises key findings from the studies contained in 
this thesis. 
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6 Conclusions and Future Directions 
6.1 Introduction 
Oleocanthal, a phenolic compound contained in VOO shares unique sensory attributes with 
the NSAID ibuprofen and also shares potent anti-inflammatory properties.  In regards to 
sensory properties oleocanthal and ibuprofen target a sensory receptor known as TRPA-1 
specifically located in the orophyrangeal region.  The perceptual characteristics associated 
with oleocanthal and ibuprofen are burning, itching, and irritation in the throat and the level 
by which an individual perceives these irritant qualities varies substantially and this may be 
due to differences in genetically mediated TRPA-1 receptor levels.  There are several 
reports of a link between the sensory perception of compounds in the food system, and also 
dietary intake of those foods.  There is also a suggestion that the perceptual characteristics 
of food compounds may be linked to the pharmacological actions in the body; linking the 
sensory with the systemic.   
We now know that oleocanthal and ibuprofen target cyclooxygenase enzymes and also 
impact several markers of chronic inflammatory disease in various tissues.  Ibuprofen has 
been reported to exert both positive and negative effects in skeletal muscle however the 
actions of oleocanthal in muscle have not been reported previously.  NSAIDs have been 
associated with having adverse effects on gastrointestinal, cardiovascular and also skeletal 
muscle health, however these drugs are often used at high doses over long periods of time.  
It may be that a naturally occurring compound such as oleocanthal, consumed in a food 
matrix and as part of a long term dietary regime, produces beneficial anti-inflammatory 
actions without these adverse effects  
Skeletal muscle health and function is intricately regulated by the regenerative capacity of 
the muscle as well as by a balance between muscle protein synthesis and protein 
degradation.  The wasting or atrophy of skeletal muscle that accompanies aging and many 
chronic disease states severely impairs quality of life.  Therefore, the maintenance of 
skeletal muscle mass is important for reducing disease, increasing longevity and overall 
health.           
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The specific aims of this thesis are  
Study 1.  To measure the oropharyngeal irritation elicited by VOO in a population sample.  
To identify individuals who are highly sensitive and insensitive to oleocanthal (in VOO) for 
participation in study 3.  To explore if the sensory perception of oleocanthal and a bitter 
tasting compound PROP are related and if either are linked to dietary intake.    
Study 2.  To optimise the methodology for study 3 and to determine the effects of 
pretreatment with oleocanathal and ibuprofen on skeletal muscle proliferation, 
differentiation, protein synthesis and degradation, and inflammation in C2C12 myotubes.   
Study 3.  To determine levels of TRPA-1 mRNA expression in muscle cells from those 
classified as hyposensitive and hypersensitive in study 1.  Also to determine any 
differential effects that oleocanthal and ibuprofen have on protein synthesis, protein 
degradation and inflammation in muscle cell lines derived from the hyposensitive and 
hypersensitive subjects identified in study 1.  
6.2 Summary of major findings 
The overarching aim of this thesis was to identify those hypersensitive (extremely 
sensitive) and those hyposensitive (extremely insensitive) to the throat irritation of 
oleocanthal and to then to determine if oleocanthal has any differential effects on muscle 
growth processes and inflammation in the two phenotypes.  The effects of oleocanthal and 
its synthetic counterpart ibuprofen were compared.  The present findings suggest that 
oleocanthal does not differentially attenuate inflammatory cytokines in those hypersensitive 
compared to hyposensitive, however oleocanthal does have an anti-inflammatory effect in 
primary human myotubes as well as C2C12 myotubes.  We also report that oleocanthal and 
ibuprofen differentially increase protein synthesis in cell lines obtained from those 
hyposensitive to the throat irritation compared to those hypersensitive  
The main aim of study 1 (chapter 3) was to confirm the large inter individual variation in 
the perceived intensity of the oropharyngeal irritation produced by oleocanthal which has 
been reported previously, and to identify and classify those hypersensitive (extremely 
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sensitive) and those hyposensitive (extremely insensitive) to the perceptual attribute of 
oleocanthal.  
The present findings confirm that there is large variability in perceived intensity of the 
irritation from ingestion of VOO containing oleocanthal.  Furthermore we were able to 
identify those who were at the extreme end of the unimodal distribution for rating 
oleocanthal as highly irritating, or weak/ not at all irritating, and obtain muscle biopsies for 
the experimental study in chapter 5.   
A second aim of study 1 was to identify if an association exists between the irritancy 
properties of oleocanthal, the bitterness of the chemical often used in sensory research, 
PROP, and the intake of certain foods.  The findings from study 1 demonstrate that the 
perceived irritation of oleocanthal is not related to the bitterness of PROP.  Furthermore 
while PROP taste intensity was related to the intake of broccoli, oleocanthal and PROP 
sensitivity were not related to each other or related to the intake of selected foods.  
Sensitivity to the irritation evoked by oleocanthal and an association with dietary intake has 
not been previously reported, therefore these findings are novel and contribute to the 
general understanding of how perception relates to food intake. 
In study 2 we observed and compared the effects that oleocanthal, the natural NSAID, and 
ibuprofen, the synthetic NSAID have in vitro on proliferation, differentiation, protein 
synthesis and degradation, and inflammatory markers.  The present study reports that 
oleocanthal and ibuprofen had no effect on proliferation or differentiation in C2C12 
myoblasts and myotubes respectively.  Interestingly both oleocanthal and ibuprofen 
increase protein synthesis but had no effect on protein degradation.  Visually from Western 
Blot data it would seem that oleocanthal and ibuprofen have no effect on mTOR, EIF2B, or 
RS6, so we can speculate that this increase in protein synthesis occurs independently of the 
mTOR pathway, however due to lack of power we cannot conclude that this is the case.  
Finally oleocanthal and ibuprofen both attenuate IL-6, TNFα and iNOS in C2C12 
myotubes.  These results suggest that oleocanthal and ibuprofen have beneficial effects on 
muscle growth processes and also attenuate inflammatory cytokines in C2C12 myotubes. 
This demonstrates for the first time the potent anti-inflammatory effects of the natural 
NSAID oleocanthal in skeletal muscle.  
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Finally in study 3 the overarching aim was to determine if perceptual differences to the 
throat irritation of oleocanthal is linked to the actions of oleocanthal in vitro was 
investigated. The results show that TRPA-1 mRNA is differentially expressed with a 
significant increase of TRPA-1 mRNA in myotubes derived from those classified as 
hyposensitive (insensitive) to the throat irritation.  Also those hypersensitive to oleocanthal 
had increased gene expression of IL-8 after LPS challenge.  Treatment with oleocanthal and 
ibuprofen increased protein synthesis in cells derived from hyposensitive when compared 
to hypersensitive subjects suggesting an association between throat sensitivity and therefore 
TRPA-1 receptor levels and skeletal muscle growth processes.  
 When data was pooled oleocanthal also increased protein synthesis with no change in 
protein degradation, as observed in study 2 in C2C12 myotubes.  Pretreatment with 
oleocanthal and ibuprofen for 24 hours attenuated LPS induced IL-6, IL-8, and TNFα  
mRNA expression, suggesting that these two NSAIDs exert similar anti-inflammatory 
action in human cells as well as mouse cells as shown in chapter 4.  These results suggest 
that there may be differences in skeletal muscle responses between two classified 
phenotypes who respond differently to sensory stimuli and this may be linked to the TRPA-
1 receptor.  These results also suggest that oleocanthal acts as an anti-inflammatory 
compound in skeletal muscle cells. 
6.3 Future Directions 
This thesis has highlighted the anti inflammatory actions of oleocanthal a natural NSAID 
and its synthetic counterpart ibuprofen, as well as suggesting that oleocanthal has a 
significant effect on muscle growth processes in both mouse and human myotubes.  
Furthermore the results from study 1 confirm that oleocanthal, a phenolic compound in 
VOO produces a throat irritation that is variable, with some individuals reporting little to no 
irritation and others reporting intense irritation.  It would seem that while there is no 
correlation with differences in perceived irritation to oleocanthal and certain aspects of 
dietary intake, sensory differences may be linked to TRPA-1 mRNA expression in skeletal 
muscle after LPS challenge.  Future in vitro and in vivo studies are required to determine 
the molecular pathways that oleocanthal act on to increase protein synthesis and to exert 
anti-inflammatory actions in skeletal muscle.   
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Also future experimental studies may confirm a link between TRPA-1 receptor levels in the 
oropharynx and TRPA-1 gene expression in skeletal muscle.  This is needed to validate an 
association between oleocanthal’s sensory properties and the skeletal muscle growth 
processes and inflammatory response to treatment with oleocanthal.  
6.3.1 The effects of a natural NSAID oleocanthal on protein translation initiation 
factors in mouse and human skeletal muscle cells 
6.3.1.1 Rationale 
Oleocanthal is known to exhibit anti-inflammatory actions in several disease models.  We 
know that oleocanthal and the synthetic NSAID ibuprofen target COX1 and COX2 
enzymes from previous studies (Beauchamp, Keast et al. 2005) and in study 2 of this thesis 
for the first time oleocanthal is shown to attenuate iNOS, IL-6 and TNFα mRNA 
expression after LPS challenge in C2C12 myotubes.  Furthermore oleocanthal increases 
protein synthesis in these same cells and also in human primary myotubes in study 3, while 
having no effect on protein degradation.   
Muscle protein synthesis and degradation involve a complex coordination of several 
molecular pathways.  The Akt /mTOR signaling pathway is crucial in regulating protein 
synthsesis.  Downstream of Akt is GSK 3β  which when deactivated promotes the 
translation initiation factor EIF2B which is essential for translation initiation (Stitt, Drujan 
et al. 2004).  Akt phosphorylates mTOR which then activates p70s6k and inactivates the 
initiation factor 4E binding protein 4E-BP.  When activated p70s6k phosphorylates protein 
S6 resulting in the translation of ribosomal proteins and elongation factors and therefore an 
increase in protein synthesis (Pap and Cooper 2002).  From preliminary Western Blots 
shown in chapter 4 it would seem oleocanthal does not increase phosphorylation of mTOR , 
EIF2B or RS6 however this is far from conclusive.  Therefore to determine whether 
oleocanthal increases protein synthesis independently of phosphorylation of Akt/mTOR , 
further experiments are required with analysis of gene and proteins involved with protein 
initiation and translation.   
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6.3.1.2 Methodology 
The experiments conducted in study 2 will be repeated and expression of specific proteins 
integral to protein initiation and translation such as Akt, mTOR, EIF2B, RS6 and p70s6k will 
be measured by Western Blot analysis.   
6.3.1.3 Significance of the study 
Oleocanthal increases protein synthesis in vitro in both mouse and primary human 
myotubes.  The synthesis is of new structural proteins is integral to skeletal muscle health 
and the prevention of muscle atrophy associated with aging and disease.  NSAIDs are often 
consumed to alleviate muscle pain and also joint pain in the elderly.  To determine the 
mechanism by which a natural NSAID such as oleocanthal stimulates protein synthesis, for 
instance by determining whether it’s actions occur via mTOR signaling pathways, or by its 
anti-inflammatory actions, is of importance to understand it therapeutic potential. 
 
6.3.2 Exploring the anti-inflammatory effects of oleocanthal in hyposensitive versus 
hypersensitive phenotypes  
6.3.2.1 Rationale 
There is variation in the way individuals perceive the throat irritation produced by 
oleocanthal and this may translate to differences in the efficacy of anti-inflammatory action 
from oleocanthal in skeletal muscle.  In study 3  the classification based on throat irritation 
established in study 1 corresponded with cells derived from hyposensitive subjects having 
increased expression of TRPA-1 mRNA after LPS challenge, and those hypersensitive 
having increased IL-8 expression.  This suggests that there may be a link between sensory 
perception and systemic responses in vitro.   In study 3 an effect from a 24 hour pretreatment 
from oleocanthal between sensitivity phenotypes could not be determined due to large 
variability and small sample number, therefore this needs to be further explored 
6.3.2.2 Methodology 
To expand on the experimental study in chapter 5 and to increase power a sensory 
screening will be conducted according to the procedure described in study 1.  From this 
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screening 4 hypersensitive and 3 hyposensitive individuals will be identified to give 
muscle biopsies.  These participants will also be asked to have biopsies taken from the 
middle turbinate of the nasal cavity for a further study to determine sensory TRPA-1 
levels. 
Once cell lines are established, in addition to the cell lines obtained in study 3, we will 
have 6 hyposensitive and 6 hypersensitive cell lines. This is important to increase power 
so stringent statistical analysis can be conducted.  RNA and protein will be extracted after 
pretreatment with oleocanthal and LPS challenge focusing on the same inflammatory 
cytokines described in study 3.  
6.3.2.3 Significance 
Muscle wasting and inflammation is associated with aging and several disease states.  A 
natural NSAID such as oleocanthal may present as a potential therapeutic target which 
may combat muscle wasting diseases and chronic inflammation in skeletal muscle, as 
suggested from results presented in this thesis.  A full understanding of the molecular 
pathway by which this is achieved in human myotubes is important.  Furthermore a 
substantiated link between the sensory perception of oleocanthal and differential effects of 
anti-inflammatory actions in vitro will give insight as to whether sensory sensitivities to 
compounds in foods are related to pharmacological actions of those foods.  
6.3.3 Differences in TRPA-1 expression in sensory neurons and skeletal muscle 
linked to pharmacological properties of oleocanthal              
 
6.3.3.1 Rationale 
Oleocanthal has been shown to robustly activate TRPA-1 receptors in the oropharynx and 
the nasal cavity previously (Peyrot des Gachons, Uchida et al. 2011).  It has been reported 
that the affinity of oleocanthal is restricted to the oropharynx and also nasal cavity and 
this is due to high expression of TRPA-1 channels in these tissues.   
In study 3 of this thesis oleocanthal attenuates inflammatory cytokines in human 
myotubes and increases protein synthesis in those hyposensitive to the throat irritation.  
This may suggest that there is a link between the sensory and systemic responses from 
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natural anti- inflammatory’ s found in foods such as VOO.  It is therefore important to 
explore a relationship between sensory TRPA-1 receptor levels, TRPA-1 gene expression 
in skeletal muscle and the actions of the potent NSAID oleocanthal in humans.  We would 
expect from the results presented in study 3 that low expression of TRPA-1 in sensory 
neurons would correlate with greater expression of TRPA-1 mRNA expression after LPS 
challenge, and reduced expression of IL-8 compared to those with high expression of 
TRPA-1 channels.  Also important is to determine if absence of TRPA-1 in trigeminal 
neurons corresponds with changes in anti-inflammatory efficacy of oleocanthal in skeletal 
muscle. 
6.3.3.2 Methodology  
Nasal biopsies and skeletal muscle biopsies that were obtained from hyposensitive and 
hypersensitive participants in 6.3.2 will be used for this study.  Using 
immunohistochemical TRPA-1 analysis for the nasal tissue excised from both phenotypes 
according to the methodology used by Peyrot des Gachons, levels of TRPA-1 expression 
in sensory neurons will be assessed and compared with TRPA-1 gene expression in the 
corresponding primary human myotubes.   
To determine if there is a link between absence of trigeminal TRPA-1 levels and 
decreased anti-inflammatory actions of the TRPA-1 agonist oleocanthal, a rodent model 
will be used incorporating some TRPA-1 deficient mice.  Muscle biopsies will be taken 
from both the TRPA-1 expressing and TRPA-1 deficient mice and RNA and protein 
extracted.  Experiments identical to those described in study 3 will then be conducted on 
cultured skeletal muscle cells arising from these two phenotypes.  
6.3.3.3 Significance 
Oleocanthal is a known TRPA-1 agonist and a naturally occurring NSAID. To determine 
if there is a link between sensory distribution of TRPA-1 and pharmacological efficacy of 
oleocanthal is of interest.  TRPA-1 could be an important target for pain and inflammation 
therapeutics in the future, and as established in this thesis oleocanthal is a natural 
compound of interest in both inflammation and skeletal muscle growth processes.  To 
establish a link between sensory attribute and systemic processes such as muscle protein 
synthesis and anti-inflammatory properties is relevant not only in disease treatment and 
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prevention, but also in an aging population. 
6.4 Conclusions 
 In summary the main findings of this thesis are: 
 
• There is large variability in the perceived intensity of oropharyngeal irritation from 
oleocanthal contained in VOO 
• 3 hyposensitive and 3 hypersensitive individuals were identified 
• Perceived oleocanthal oropharyngeal irritation is not related to perceived bitterness 
of PROP 
• Oleocanthal is not related to the intake of certain dietary components 
• Oleocanthal and ibuprofen have no effect on myoblast proliferation or myotube 
differentiation in C2C12 mouse muscle 
• Oleocanthal and ibuprofen significantly increase protein synthesis in C2C12 
myotubes but do not influence protein degradation. 
• Oleocanthal and ibuprofen attenuate IL-6, iNOS and TNFα in C2C12 myotubes 
• Preliminary Western Blots show no increase in mTOR, RS6 or EIF2B 
phosphorylation, however this is not conclusive 
• Oleocanthal and ibuprofen increase protein synthesis in human myotubes and do 
not influence protein degradation 
• Oleocanthal and ibuprofen differentially increase protein synthesis in cells derived 
from those classified as hyposensitive compared to hypersensitive to the 
oropharyngeal irritation of oleocanthal 
• In myotubes originating from those hyposensitive to the throat irritation of 
oleocanthal there is a greater increase in TRPA-1 gene expression after LPS 
challenge.  In myotubes arising from those hypersensitive to the throat irritation 
there is a greater increase in IL-8 after LPS challenge 
• Pretreatment with oleocanthal and ibuprofen did not differentially attenuate 
inflammatory cytokines IL-6, IL-8, TNFα, or MCP-1 in the 2 phenotypes. 
• Pretreatment with oleocanthal and ibuprofen did attenuate inflammatory cytokines 
IL-6, IL-8, TNFα in human myotubes, but had no effect on MCP-1. 
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